The cleavage of rabbit immunoglobulin G at constant tryptophan residues / by Campbell, Dale Lynn,
' 72-9027
CAMPBELL, Dale Lynn, 194-1- 
THE CLEAVAGE OF RABBIT IMMUNOGLOBULIN 
G AT CONSTANT TRYPTOPHAN RESIDUES.
The University of Oklahoma, Ph.D., 1971 
Chemistry, biological
University Microfilms, A XEROX Company, Ann Arbor, Michigan
THIS DISSERTATION HAS BEEN MICROFILMED EXACTLY AS RECEIVED
THE UNIVERSITY OF OKLAHOMA 
GRADUATE COLLEGE
THE CLEAVAGE OF RABBIT IMMUNOGLOBULIN G AT 
CONSTANT TRYPTOPHAN RESIDUES
A DISSERTATION 
SUBMITTED TO THE GRADUATE FACULTY 
in partial fulfillment of the requirements for the
degree of 
DOCTOR OF PHILOSOPHY
BY
DALE LYNN CAMPBELL 
Oklahoma City, Oklahoma 
1971
THE CLEAVAGE OF RABBIT IMMUNOGLOBULIN G AT 
CONSTANT TRYPTOPHAN RESIDUES
APPROVED BY
DISSERTATION COMMITTEB
PLEASE NOTE:
Some Pages have indistinct 
print. Filmed as received.
UNIVERSITY MICROFILMS
ACKNOWLEDGMENTS
I wish to thank the Oklahoma Medical Research Foundation for its 
support during the last few years.
I would also like to thank the members of the reading committee 
for their help in the preparation of this thesis.
Also, I would like to express my appreciation to Mr. John Slagle 
and Mrs. Janet Rogers for their technical help, and many thanks to Dr. 
Jordan Tang, Neurosciences Department, Oklahoma Medical Research Founda­
tion, and all the people in his lab for the help they have given me.
Especially, I would like to thank my advisor, Dr. Robert Delaney, 
Department of Biochemistry and Molecular Biology, University of Oklahoma 
Medical School, for his advice, counsel and friendship over the last few 
years.
I would also like to thank my wife, Jolene, who helped so much 
in the preparation of this manuscript.
Ill
TABLE OF CONTENTS
Page
LIST OF TABLES.................................................  v
LIST OF ILLUSTRATIONS.......................................... vi
Chapter
I. INTRODUCTION............................................ 1
II. METHODS AND MATERIALS.................................  31
III. RESULTS................................................ 45
IV. DISCUSSION.............................................. 76
V. SUMMARY................................................ 95
BIBLIOGRAPHY...................................................  97
IV
LIST OF TABLES
Table Page
1. Properties of Human Immunoglobulins (30) ..................  4
2. Amino Acid Composition of Light Chains, Heavy
Chains and Cl Fraction....................................53
3. Relative Composition of Fragments Obtained
from NES Oxidized Light C h a i n ............................ 57
4. Relative Composition of Fragments Obtained
from NBS Oxidized C^ Fractions............................64
5. Composition of Tryptic Peptides Obtained from
Cl Fractions..............................................67
6. Fractions from Light Chains and Cl Expressed as
Residues/Mole .........................................  75
7. Comparison of Predicted and Determined Compositions
of Cl Fractions..........................................81
LIST OF ILLUSTRATIONS 
Figure Page
1. The Site of Proteolytic Cleavages in the Heavy
Chain (5l).............................................  8
2. The Interchain and Intrachain Disulfide Bonds
of Eu (86)................................................ 12
3. The Interchain Disulfide Bonds of the 4 Types
of Human IgG ( 8 4 ) ........................................ 13
4. The Evolution of Immunoglobulin Chains...................... 22
5. The Constant Tryptophan Residues in Eu ( 8 6 ) ................ 24
6. The Reaction of Tryptophan with N-bromosuccinimide
to Produce Chain Cleavage .............................  28
7. DEAE Cellulose Chromatography of Rabbit I g G ................ 46
8. Polyacrylamide Gel Electrophoresis of IgG Fractions . . . .  47
9. Double Immunodiffusion of DEAE Cellulose Fractiona­
tion Peaks................................................47
10. The Immunoelectrophoresis of IgG Fractions from
DEAE Cellulose Chromatography .......................... 48
11. Chain Separation in Propionic Acid.......................... 51
12. Chain Separation in 8 M Urea................................ 52
13. The Spectra of Unreacted and Oxidized Light Chains ........  54
14. Chromatography of N-bromosuccinimide Treated
Light Chains..............................................56
15. Chromatography of CNBr Treated Heavy Chains ..............  58
16. Flow Chart of Reactions of the Heavy Chains and
the Resulting Fractions.............   59
17. The Spectra of Unreacted and Oxidized C l .................... 60
18. Chromatography of N-bromosuccinimide Treated Cl
Fraction on G - l O O ........................................52
19. The Rechromatography of Peak D .............................. 63
20. The Peptide Map of Peak C .................................. 65
vi
LIST OF ILLUSTRATIONS— Continued 
Figure Page
21. The Chromatography of a Trypsin Digest of Peak C ........  69
22. The Amino Acid Sequence of Peptides Isolated from
Trypsin Digests of Peak C ................................ 70
23. The Peptide Map of Peak E ................................ 72
24. The Peptide Map of Peak B ................................ 73
25. The Peptide Map of Peak D I I .............................. 74
26. Comparison of the Amino Acid Sequences from Peak C
Peptides with the Sequences for Rabbit IgG Reported 
by Fruchter (79) and with the Myeloma Protein Eu (86) . . 86
27. The Sequence of Rabbit Cl Fractions from Residue 109
to the C-terminal (79) and the Location of Isolated 
Peptides............................................... 87
Vll
THE CLEAVAGE OF RABBIT IMMUNOGLOBULIN G AT 
CONSTANT TRYPTOPHAN RESIDUES
CHAPTER I 
INTRODUCTION
In ancient times it was realized that persons who recovered from 
a disease such as smallpox never contracted it again (l). Although this 
knowledge of the existence of immunity has been with us for many centu­
ries, it has only been the last few years that the scientific community 
has been able to come to grips with the molecular level reactions that 
enable the immune response to work. Felton (2) first reported that anti­
bodies were protein in nature in 1932. Later, in 1937, Tiselius (3, 4) 
reported that antibody to egg white lysozyme was associated with the slow­
est moving or gamma band that he had been able to separate from immune 
rabbit serum with his new electrophoresis equipment. He also reported a 
7 S value for this band or a molecular weight of 167,000. Other exper­
iments showed that when the rabbit was immunized the amount of protein 
in the gamma band increased.
The next several years saw much time and effort expended on the 
study of the physical nature (s), the isolation and purification (6, 7,
8) and the chemical nature (9) of gamma-globulin (IgG). Values given for 
the molecular weight varied somewhat, but the most generally accepted
2values are in the range of 150,000. Rabbit IgG contains about 2.4% by 
weight carbohydrate. The antibody molecule is elongated with dimensions 
of about 250 x 40 A and has little or no alpha helix (9).
As the knowledge of immunoglobulins increased, the nomenclature 
covering the immunoglobulins also developed. All further references to 
immunoglobulins will be in accordance with World Health Organization con­
ventions (lO, 11, 12, 13, 14).
Early indications were that IgG was composed of a single poly­
peptide chain (l5), however it has always proved to be heterogeneous by 
physical or chemical criteria. It was not until 1959 that Edelman (l6,
17) showed the multichain structure of human IgG. He reduced the disul­
fide bonds in urea and showed by subsequent column chromatography on car- 
boxymethyl cellulose, ultracentrifugation and starch gel electrophoresis 
that the molecule has multiple polypeptide chains. Franek (is) extended 
the findings to show a multichain structure for IgG from the pig, cow, 
horse and rabbit. Porter and his co-workers did much to establish a 
structure for the rabbit IgG molecule. Fieischman, Pain and Porter (l9) 
proposed that IgG consists of two chains of molecular weight 110,000 and 
40,000 respectively or perhaps four chains; two with a molecular weight 
of 55,000 and two with 20,000. Results obtained by reduction of disulfide 
bonds followed by chromatography on Sephadex G-75 in propionic acid and 
determination of the molecular weight of the resulting fractions in the 
ultracentrifuge led to this conclusion. In addition, the IgG molecule 
is dissociable into chains by use of SDS (20) and by use of alkaline con­
ditions (21). Porter (22) then proposed a 4 chain structure with five 
interchain disulfide bonds. The work leading to this conclusion was pub­
3lished by Fieischman et (23). This work contained N-terminal analy­
sis and carbohydrate content of the different polypeptide chains. Pain 
(24) added the molecular weight data in the same series of publications. 
He found the heavy chain had a molecular weight of 50,000 and the light 
chain 20,000. Crumpton and Wilkerson (25) also added the amino acid com­
position. Fieischman et al. (23) concluded that the 4 chain structure 
accounted for all these observed data. Small (26) and Cohen (27) pub­
lished confirmation of these conclusions a few months later.
Many early attempts at proteolytic digestion of IgG were made, 
but little structurally useful data preceded Edelman's work on the multi­
chain structure. Porter (28, 29) made a great breakthrough when he found 
the digestion of rabbit IgG by papain yielded three fragments of almost 
identical molecular weight upon carboxymethyl cellulose chromatography. 
The first two of these fragments (Fab) retained the ability to combine 
with antigens and were very similar in chemical and biological properties 
while the third (Fc) crystallized easily and contained most of the anti­
genic specificity of the intact molecule. The common properties of im­
munoglobulins for which Fc is responsible, and other properties as sum­
marized by Cohen and Milstein (30) are shown in Table 1. The Fab frag­
ment is composed of the light chain plus a fragment of the heavy chain 
(Fd). Porter then proposed that the rabbit IgG molecule is formed of two 
sections with similar structure joined to a third section of a different 
character. He also proposed that Fc was identical for all IgG and that 
Fab was different for each specific antibody. Nisonoff proved by meas­
urement of antigen-binding capacity (31) that the Fab fragments contained 
single combining sites (were "univalent"), and that papain digestion does
TABLE 1
PROPERTIES OF HUMAN IMMUNOGLOBULINS (30)
Properties IgG IgA IgM IgD
Biological
Serum conc. (mg %) 800-1680 140-420 50-190 0.3-40
Synthesis rate (mg/kg/day) 20-40 2.7-55 3.2-16.9 0.03-1.49
Catabolic rate (% I V pool/day) 4-7 14-34 14-25 18-60
Distribution (% in I V pool) 48-62 40 65-100 63-86
Antibody activity + + +
Complement fixation + 0 +
Placental passage + 0 0 0
Presence in cerebrospinal fluid + + 0
Selective seromucous secretion 0 + 0
Skin sensitization
heterologous species + 0 0
homologous species 0 ? 0
Immunological
Light-chain types kappa, lambda kappa, lambda kappa, lambda kappa, lambda
Heavy-chain classes gamma alpha mu d
types 4 2 2
Physicochemical
^20, w 6.5-7.0 7,10,13,15,17 18-20, 30 6.2-6.8
Total Carbohydrate {%) 2.9 7.5 11.8
5not effect the binding capacity (32).
Shortly after Porter's work Nisonoffs group produced fragments 
(Fab') similar to the Fab fragments by digesting with pepsin in the pres­
ence of a reducing agent or by digestion with pepsin followed by treat­
ment with a reagent that reduces disulfide bonds (33). The digestion 
with pepsin gives a 5 S dimer (Fab')2 that dissociates to a 3.5 S monomer 
(Fab') upon mild reduction. This reduction splits only one disulfide 
bond (34). The molecular weight of the dimer is 106,000 and that of the 
monomer is 56,000 (35). In this method the Fc portion is digested to 
smaller polypeptides.
Work on the multichain nature of the molecule progressed rapidly 
using the chain separation and proteolytic digestion methods. Palmer 
et al. (36) showed that the Fab fragments from a single IgG molecule are 
either Porter's Fab Fraction I or Fab Fraction II, but never both on the 
same molecule. To do this they first fractionated rabbit IgG on carboxy­
methyl cellulose then digested each of the fractions with papain and 
found that each fraction put most of its Fab in one of the two peaks. 
Goodman (37) showed that Fab and Fab' were antigenically identical. 
Fieischman et al.. (l9) showed that Fab contained the antigenic sites for 
light and heavy chains, but Fc had only antigenic sites for the heavy 
chains. Nisonoff's group (38, 39) reported that 509o to 66% of the rabbit 
IgG molecules could be dissociated into half molecules by the reduction 
of a single disulfide bond. The other molecules required the reduction 
of two or more bonds. After further study they reported that the same 
disulfide bond responsible for this dissociation was also responsible for 
the dissociation of the peptic dimer into Fab' monomers (40). They re­
6ported that Fc fragments had the same characteristics (41).
Cebra and his group (42, 43) did a series of studies by cleaving 
IgG with insoluble papain. This was done because activation of papain 
requires a reducing agent, and in this manner he could activate the papain 
and subsequently remove the reducing agent. The papain was made insoluble 
by polymerizing it and then he carried out a digestion with stirring to 
keep it in suspension. The reaction could be quickly stopped by centri­
fugation. By this procedure he (42) was able to produce a 5 S Fab dimer 
that resembled the product t-f-pepsin digestion. This Fab dimer would 
dissociate into 3.5 S monomers with the addition of a reducing agent.
This work seems to indicate the papain cleavage of Porter (29) is depend­
ent on a reducing agent but later structural work casts some doubt on 
this interpretation. It is possible that this new Fab dimer resulted 
from a slight change in specificity of the enzyme. In further work (43) 
he compared his dimer with (Fab’)2 from pepsin and found them to be quite 
similar except (Fab')2 was a little heavier and could be reversibly dis­
sociated into 3.5 S subunits by reduction and reoxidization whereas his 
dimer would not reassociate after the disulfide bond was broken.
With the increase in data more accurate conclusions about the 
structure of IgG could be drawn. Marier et (44) added confirmation 
of the four chain structure and the location of the papain split in the 
heavy chain by their work on the ultracentrifuge after reducing and dis­
sociating Fab and Fc fragments. Noelken et al. (45) proposed that IgG 
contains 3 globular portions joined through two short segments of loosely 
coiled polypeptide chains that are easily hydrolyzed by enzymes. An in­
terchain disulfide bond connects these two chains adjacent to the loosely
7coiled segment.
Further studies on the cleavage of IgG were undertaken. Putnam 
et al. (46) studied plant proteolytic enzymes and found that those which 
required reducing agents gave splits much like papain. Givol (47) re­
ported a method of cleavage with similar results with trypsin on amino- 
ethylated IgG. Cahnmann et (48, 49) reported a chemical cleavage 
giving a 5 S dimer with cyanogen bromide. Its activity was much the same 
as that from pepsin (SO). A review of the sites of most of the proteo­
lytic digestion cleavages was presented by Givol et (Sl) (Figure l).
Another of the most important breakthroughs to determining the 
structure of immunoglobulins came when Edelman and Gaily (52) demonstrated 
that the proteins described by Dr. Henry Bence Jones in 1847 and found in 
the urine of multiple myeloma patients was the light chain from an immuno­
globulin. Edelman and Gaily were unable to show any differences by starch 
gel electrophoresis, amino acid composition and several other criteria 
between the Bence Jones protein of one patient and the light chains de­
rived from the myeloma protein of the same patient. Since this protein 
is homogeneous, it is more easily studied than normal heterogeneous light 
chains. In later studies Schwartz and Edelman (53) showed that the pep­
tides of Bence Jones proteins and the myeloma protein light chains were 
also identical by 2 dimensional high voltage electrophoresis.
At about this same time Mannik and Kunkel (54) discovered that 
2 antigenic types of light chains existed in human Bence Jones proteins. 
They later extended this observation to 7 S IgG (55). This was also 
shown by Potter et £l. to be true in the mouse (56, 57) and these two 
types of chains were called kappa and lambda. Gray and Kunkel (58) also
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Fig. 1 - The site of proteolytic cleavages in the heavy chain (Sl).
I stands for a trypsin split, and Pap for papain. T° is a trypsin split at aminoethylcysteine, 
and P stands for a pepsin cleavage. The numbers indicate the number of residues between each of the 
splits.
9found that IgG could be separated into different antigenic subclasses ac­
cording to the antigenic determinants on the heavy chain. There are now 
4 recognized subclasses of human IgG called IgGl, IgG2, IgG3 and IgG4 
(12).
In different developments, Haber (59) and Whitney and Tanford 
(61) proved that the amino acid sequence alone determined the 3 dimen­
sional structure of the binding site of a immunoglobulin molecule. Work­
ing with the Fab fraction of specific antibody they reduced all disulfide 
bonds in urea or guanidine hydrochloride. They removed the reducing 
agent and denaturing agent and allowed the polypeptide chains to reoxi- 
dize with the solution exposed to air. The binding activity was recov­
ered. Sela (62) managed to accomplish the same thing with whole IgG by 
reacting the lysine of the IgG with polyalanine before reduction of the 
disulfide bonds.
The amino acid sequences of the homogeneous Bence Jones proteins 
began to be published and analyzed. The first complete light chain se­
quence to be published was by Wikler et of the lambda chain Sh (63) 
but even before this, portions of several chains had been published and 
a clear pattern was quickly observed. Even in the first comparison of 2 
kappa chains (64), Cummings and Roy, it was obvious that the C-terminal 
half of the two chains were almost identical while the N-terminal frac­
tions showed much variation. Shortly thereafter another partial sequence, 
Ag, by Titani et al. (65) added to the comparison and the pattern was the 
same. Further evidence was quickly received from Milstein (66, 6?) which 
confirmed these observations. Milstein also located the half cysteine 
involved in the interchain disulfide bonds (68) at the C-terminal of the
10
light chain (see Figure 2 below) and positioned the intrachain disulfide 
bonds (69) for the light chain.
The story for the heavy chain was more slowly unfolded. Early 
work by Frangione and Franklin (70) showed the heavy chain to contain a 
variable and constant portion like the light chain. This was done with 
peptide maps of the Fd and Fc sections of the chain. Subsequently they 
proposed the N-terminal half of the Fd region was variable (7l). At about 
the same time, Nelson et al. (72) published the tryptic peptide maps of 
Fab, Fc, light and heavy chains from specific and nonspecific rabbit IgG. 
They were able to show heterogeneity in the light chains, but since they 
did not have enough Fd to properly work with, they only speculated about 
the existence of heterogeneity in the heavy chain.
Since the heavy chain is twice as long as the light chain, its 
myeloma proteins are not usually excreted in the urine, so they are more 
difficult to obtain. Therefore, other approaches to the heavy chain 
structure were tried. Sequence studies were undertaken on non-myeloma 
proteins. Early efforts to determine the primary structure came from 
Givol and Porter (73, 74) who isolated the cyanogen bromide peptides of 
heavy chain from rabbit IgG and characterized the C-terminal fragment in 
addition to placing the fragments in order. The following year Hill 
et al. (75) reported the amino acid sequence for the majority of the Fc 
fragment and Wilkinson et al. (76) reported the amino acid sequence of 
the N-terminal fragment that is split from some rabbit IgG molecules by 
cyanogen bromide cleavage. Since these early advances. Porter's group 
(77, 78, 79) has nearly completely finished the amino acid sequence of 
the constant portion of the heavy chain of rabbit IgG. Fieischman (8O)
11
has sequenced the N-terminal 65 residues from the heavy chain variable 
region of a rabbit with restricted heterogeneity. At this time, only 
about 30 residues of the rabbit heavy chain are not sequenced.
The intrachain and interchain disulfide bonds came under study 
also. Pink and Milstein (Sl) isolated the peptides containing the inter 
heavy-light chain disulfide bridge from several myeloma proteins and nor­
mal pooled IgG. At the time they were unable to position the peptides 
from the heavy chain except they knew the peptides came from the Fd por­
tion of the molecule. They then reported (82) two intrachain disulfide 
loops in the Fc portion of the heavy chain that were much like those 
found on the light chain (69). This same type of structure was then ex­
tended to the Fd chain (83). Disulfide bridges between the heavy chains 
show large differences. There is 1 disulfide bridge in most rabbit IgG 
(39) and as many as 5 in some human IgG3 molecules (84). It is likely 
that they are all parallel (84). On the other hand, light-heavy inter­
chain bonds have been located in 2 different positions on the heavy chain 
(85). Edelman (86) placed the light-heavy interchain bond near the cen­
ter of the heavy chain for the myeloma protein Eu. O'Donnell et al. (87) 
and Strausbauch et (88) have placed this bond alongside the first 
half cysteine residue in the second intrachain disulfide loop for rabbits 
and goats respectively. O'Donnell (87) also places an extra intrachain 
disulfide bond in the rabbit IgG. It helps form the second loop in the 
Fd portion of the molecule. All the disulfide bonds for the IgGl myeloma 
protein Eu are shown in Figure 2. Frangione et (89) have worked out 
the interchain disulfide bonding for each of the subclasses of human IgG 
(Figure 3).
•SS 1 I— s s
23 88 134 19^
S
2 2 ^ " ^ ^ 9 6 T f S ^ ™ 2 o ! ^ P ^ 6 ^ ^ " 3 2 ^ ^ ? 6 ^ " ' T 2 ?
SS 
55
— S 5  1 I— 5  5  — ]226| 1229 I— 5 5 — ]_____ |— S 5 — ;
C  ----------------------
2201 N5
5
5
5 5 ----1 I------5 5 — I |214
Fig. 2 - The interchain and intrachain disulfide bonds of Eu (86).
The residue number of the intrachain disulfide cysteine residues is indicated in the upper 
half of the molecule, and the interchain cysteine residues are indicated in the lower half.
T
S
S
J
TT
§
11
SS7
TT ir
ss ss 
SS ss
Il II
ss
Ig G I lgG 2
ss ss
!£■sss
-IlL-
ss
A
V
T Tn
_u_
ss
lgG 3 lg G 4
w
Fig. 3 - The interchain disulfide bonds of the 4 types of human IgG (84). 
Dashed lines in IgGS indicate disulfide bonds that have not been positioned exactly.
14
One of the advances most important to the understanding of the 
structure and evolution of immunoglobulins came when Singer (90) saw a 
relationship between peptides from the C-terminal portion of light chains 
and the corresponding C-terminal 18 residue sequence from heavy chains. 
This information was combined with the information from his own work (90) 
which indicated that a relationship also existed between the variable por­
tions of light and heavy chains. He then proposed that the structural 
genes that code for light and heavy chains are related. Hill et (91) 
were able to expand on this finding as the sequence data for the Fc re­
gion of rabbit IgG was established. They were able to show internal ho­
mology between the N-terminal and C-terminal halves of the Fc region and 
from the two halves of Fc with both halves of the light chain Ag. They 
then proposed a precursor protein of 110 residues that upon gene doubling 
became a primitive light chain. From this primitive light chain evolved 
the kappa and lambda chains of today. This primitive gene also went 
through another doubling to form the heavy chains of today.
Much work was also done on myeloma heavy chains. Porter's group 
(92, 93) sequenced the N-terminal part of the myeloma heavy chain Daw and 
several other partial sequences have been reported (94). Another impor­
tant breakthrough came when Edelman et (86) reported the sequence of 
an entire IgG molecule. This included the light and heavy chain of the 
myeloma protein Eu plus the position of the disulfide bonds. For the 
first time the relationships of an entire molecule could be studied. The 
sequence was added proof that Hill's original theory (9l) was basically 
correct. Edelman and Gall (95) further proposed a "domain" theory in 
which each intrachain disulfide bond helped form a tight conformation or
15
domain with looser chain connecting the domains. Each domain on either 
variable or constant regions would contribute an active site to mediate 
a function of the immunoglobulin. Evidence at the present (96) time 
seems to uphold this theory.
During the time that much of the structural work was starting, 
the search to find the binding site of the antigen was also started. 
Porter's work (29) showed that the binding site was on the Fab fraction. 
Thus the binding site could be on the N-terminal half of the heavy chain, 
on the light chain or shared by both. Early evidence showed that anti­
gens would combine with isolated heavy chains but not with isolated light 
chains (23). A series of experiments on recombination of light and heavy 
chains was conducted. Edelman et (97) showed that the recombination 
of light and heavy chains of a particular antibody led to a partial re­
covery of antibody activity. Heavy chains recombined with light chains 
from different antibodies showed an increase in binding of the heavy 
chain's antigen but not as great as with the homologous light chain.
Light chains against a given antigen mixed with heavy chains against an­
other antigen showed no activity against the light chain's antigen.
Later, Yoo et (98) were able to demonstrate binding by the light 
chain by using a fluorescence-enhancement technique to determine the 
small amount of binding. Roholt et al. (99) showed that the formation 
of hybrid molecules using light and heavy chains from different antibod­
ies did not involve the formation of disulfide bonds but that the assoc­
iation of the chains was strong enough to hold the molecule together with­
out the formation of covalent bonds. Gray and Mannik (lOO) showed that 
heavy chains would bind with light chains from the same antibody in pref­
16
erence to other light chains even if the other light chains were in great 
excess. Bridges and Little (lOl) separated the light and heavy chains 
from 2 myeloma proteins that bound DNP and studied the recombinants.
Light and heavy chain recombinants from the same proteins bound DNP better 
than either of the 2 hybrids. Dorrington et al. (l02) studied recombina­
tion events with ORD and found the ORD pattern of the original molecule 
was recovered when heavy and light chains of the same antibody were al­
lowed to reassociate, but an altered pattern appeared if a hybrid formed.
A different approach to the structure of the antibody combining 
site was made by Pressman and Roholt (l03). A specifically purified 
antibody was cleaved into Fab fragments. Part of the antibody was incu­
bated with j125 and another part with antigen and The two frac­
tions were then combined and digested with pepsin. The resulting pep­
tides were separated by high voltage electrophoresis. The i125_^q_i131 
ratios in some peptides were different from that of the whole digest so 
these peptides probably came from the combining site of the antibody.
In further work Roholt et al.. (l04) proved that the first two of Porter's 
fractions (29) were not identical by treating one of the fractions with
and the other with They then showed that after mixing together
and digestion the I^^^-toI^^^ ratios were not alike. By the same pro­
cedure Kitagawa et (lOS) showed that antibodies of the same specifi­
city from different rabbits were different and later Roholt and Pressman 
(l06) concluded from these differences that the antibody from each rab­
bit is composed of predominantly only a few different types of antibod­
ies.
Another type of approach, affinity labeling, was used by Singer
17
and his group to try to discover the active site of the molecule. Wofsy 
et al. (107) proposed that affinity labeling should label the active site 
and showed by the absorption spectra that the rabbit protein was labeled. 
Metzger et (1O8) then showed that both light and heavy chains were 
labeled. Fenton and Singer (l09) then reported that the ratio of labeled 
tyrosine in the heavy chain to the light chain was 2:1 in each of 3 dif­
ferent antibenzoid antibody systems, therefore these tyrosine residues 
were in relatively consistent positions. The next step was to isolate 
the peptides containing the labeled tyrosine. Doolittle and Singer (llO) 
reported that the tyrosine residue from both chains were found in highly 
variable, hydrophobic peptides of about 25 residues in length. They con­
cluded that these peptides were from the variable portion of the antibody 
chains. A later publication by Good et (ill) extended these observa­
tions to sheep, mice and guinea pig. After further work (II2), dipeptides 
containing much of the labeled tyrosine were isolated and each type of 
chain showed a predominant dipeptide. For instance a mouse kappa chain 
showed an aspartic-tyrosine labeled dipeptide. Since none of the con­
stant region tyrosine residues from mouse myeloma proteins has an aspar­
tic residue preceding it. Singer concluded that the residue must come 
from the variable portion of the chain. The most likely position would 
be that of residue #86 which is preceded by an aspartic in most mouse 
light chains. This pattern of a constant tyrosine residue preceded by 
another constant residue, which differs for each chain and species, holds 
true for several species. Data obtained by Goetzl and Metzger (llS) from 
labeled DNP binding myeloma protein was interpreted by them to show that 
tyrosine #34 and not #86 was labeled in this protein.
18
Sela (62) in different studies was able to show that a correla­
tion exists between the net charge of the antigen and the antibody that 
binds it. He showed this by making antibodies against several basic and 
acidic proteins followed by DEAE Sephadex chromatography of the antibod­
ies. The antibodies against the acidic proteins always came off the col­
umn in one peak and those against basic proteins were in a different 
peak. Another experiment showed the size of the binding site was of the 
order of a tri- or tetra-peptide. Earlier studies by Kabat (ll4) had 
shown the upper limit to be the size of a hexasaccharide.
Since Porter's (29) discovery of the Fc portion of the IgG mol­
ecule several functions have been associated with this portion of the 
molecule. It has been indicated to function in complement fixation, skin 
sensitization, placental transfer, intestinal absorption and control of 
catabolism (lib). Although its amino acid sequence has been published, 
its function has not been related to the structure. Study of the Fc 
chains by Goodman (ll6), Utsumi and Karush (liv), Henney et a],. (llS) and 
others led to no conclusive proof as to the location of these functional 
sites. The most informative work along this line was by Prahl (lib) who 
has proposed that the functional site for skin reactivity is on the N- 
terminal 3b-4CÇo of the Fc region. The peptide that represents the rest 
of the molecule (residue #334-446 on Eu), retains most of its structural 
integrity as evidenced by its ability to be crystallized, but it has al­
most no skin reaction. This peptide in high doses was able to cause a 
slight skin reaction but it was doubtful if the results were meaningful. 
Any digestion of the N-terminal portion of Fc was effective in causing 
loss of skin reactions.
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Electron microscopy has been helpful in bringing other insights 
into the structure of immunoglobulins. Feinstein and Rowe (ll9) working 
with IgG noticed that the molecule was almost linear when no antigen was 
bound but that the molecule assumed a "Y" shape when antigen was bound. 
The angle of the Y varied somewhat. They then proposed a "hinge" section 
in the molecule. The hinge is the same section of the molecule described 
by Noelken (45) as loosely coiled and the site of the proteolytic cleav­
ages that enable the large sections of the molecule to be separated. 
Valentine and Green showed by electron microscopy IgG bound to antigens 
forming circles consisting of from 3 to 5 IgG molecules.. Each IgG mole­
cule was bound to 2 antigens and each antigen was bound by 2 molecules of 
IgG (120).
It appears that the 3 dimensional structure of the IgG molecule 
will soon be known. Poljak (l2l) reports that he has the 6 Â diffraction 
pattern for an IgG molecule and that the data is good to 2.5 Â. There­
fore it will not be long before the 3 dimensional relationships of an en­
tire IgG molecule will be known.
Over the past few years many theories about the evolution of the 
immunoglobulin structure and mechanism of its synthesis have been pro­
posed. At the present time the most popular theory on its biosynthesis 
is the "two gene one polypeptide chain" theory. An early exponent was 
Gray (l22); whose theory has been recently reviewed by Williamson (l23). 
The theory basically states that the variable and constant region of a 
given immunoglobulin polypeptide chain arise from different genes. This 
phenomenon is probably controlled at the DNA level, so a mechanism must 
be available to transcribe 2 distinct genes into one mRNA molecule.
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This theory further proposes many variable region genes and only a few 
constant region genes. Also it is thought that light chains have a cer­
tain set of variable region genes and heavy chains have a different set.
If the 2 gene 1 polypeptide chain theory is correct, other theo­
ries would then have to be modified. Hill's (91) theory of the evolution 
of the immunoglobulins is one of these. If the genes for the variable 
and constant regions of the light chain are separate, then doubling of 
the light chain gene would not have achieved a heavy chain. Litman et al. 
(l24) have proposed some modifications. He proposes that the heavy chain 
found in existing species comes from 1 (5.75 S immunoglobulins in the 
duck) or more duplications (2 in IgG, 3 in higher molecular weight heavy 
chains such as the 7.8 S duck IgM) of the 110 residue segment following 
the variable region.
A new theory proposed by Delaney (l25) goes one step further 
back in time than Hill's (9l) theory. By close examination of the amino 
acid sequences of Eu (86) he has been able to demonstrate homology be­
tween successive segments of the light and heavy chains only 55 residues 
long. In light of these findings and other theories that have been dis­
cussed, a chain of 55 residues doubled to 110 residues. This 110 resi­
due segment duplicated forming the variable and constant precursors. The 
mechanism for joining variable and constant genes was probably the next 
factor introduced. The multichain structure appeared presenting 2 chains 
similar to light chain dimers. Next followed doubling of the constant 
gene of 1 chain, introducing the heavy chain similar to the heavy chain 
in duck 5.75 S immunoglobulin. Advent of the 4 chain structure occurred, 
and further elongation of the heavy chain happened once to produce the
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gamma chain, twice to produce the duck 7.8 S immunoglobulin. The evolu­
tion of the immunoglobulin chains is shown in Figure 4.
Since it is thought that kappa chains, lambda chains and heavy 
chains have different sets of variable genes (l23) (only 1 set of vari­
able genes for all heavy chains), it is probable that before light and 
heavy chains diverged there was a doubling of the entire DNA section con­
taining the constant region and all of the variable portions for that 
early immunoglobulin. The same is true for the divergence of kappa and 
lambda chains.
As the studies of the primary structure of the IgG molecule con­
tinue to be made, most of the attention will be turned to the variable 
portion of the molecule. A method for the separation of the variable and 
constant fraction of the molecule would therefore be valuable in these 
studies. One can see in the future that antibodies may be artificially 
manufactured to fight one or another disease or infection. The variable 
region of an antibody against the given antigen could be sequenced. This 
section could be manufactured and linked to an IgG constant chain giving 
an effective antibody.
Karlsson et _al. (l26) have proposed a method involving light 
chains and have used this method to separate the variable and constant 
regions by limited proteolysis with trypsin, pepsin, or papain. This 
method results in low yields with only a maximum yield of 22% reported. 
Therefore a search for a better method would be worthwhile. This disser­
tation proposes a method that could be more effective in the separation 
of variable regions from constant regions in both light and heavy chains.
When the internal homology in Edelman's (86) Eu sequence was
I
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Fig. 4 - The evolution of immunoglobulin chains.
A 55 residue precursor chain doubles to form a 110 residue precursor chain (l). This precur­
sor divides to form variable regions (dashed line) and constant region (2), and a mechanism for joining 
them is introduced (3). Another doubling occurs (4), to form light and heavy chain precursors. Kappa 
and lambda chains are formed from the light chain precursor (s), and elongation of the constant regions 
of the heavy chains forms the present day heavy chains.
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examined, it appeared that certain tryptophan residues in the molecule 
were in invariant positions. One of these residues was close to the 
variable-constant region dividing line. If cleavage occurred at this 
residue, it would be possible to obtain a variable-constant region split 
which would also produce a constant region fragment that would contain 
much of the Fd sequence unreported at that time. The constant tryptophans 
in the IgG molecule are shown in Figure 5. These tryptophan residues al­
ways occur from 10 to 15 residues after the first half cystine residue in 
each intrachain disulfide bond. There are also other tryptophan residues 
in the heavy chain that might be constant. One follows the first trypt­
ophan by about 15 residues and the other 2 are in the Fc region. There 
have not been enough heavy chains sequenced to be able to state whether 
these three are constant or not, but they have appeared in all IgG heavy 
chains sequenced so far. Edelman (96) also noticed the consistency of 
the tryptophan residues and that the section of the molecule that we were 
trying to sequence was very hydrophobic.
Dayhoff (l27) has shown that tryptophan is the amino acid resi­
due that retains its location in an evolving polypeptide chain better 
than any other residue. Cysteine is the next most constant residue. 
Dayhoff (l27) has published a matrix indicating the tendency of a given 
amino acid to remain the same or change to another amino acid within a 
given accumulated number of mutations. If an amino acid chain of 100 
residues undergoes a single point mutation one of the residues in this 
chain may change. Dayhoff has calculated that after 256 point mutations 
in a polypeptide chain 100 residues long a tryptophan residue will remain 
in its original position 48% of the time while cysteine will remain 41%
14835
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Fig. 5 - The constant tryptophan residues in Eu (86).
The constant tryptophan residues are indicated by arrows and residue numbers in the upper half 
of the molecule. The dashed arrows indicate residues in the heavy chain that may be constant, but not 
enough chains have been sequenced to say for sure.
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of the time. At the other extreme, methionine will remain only 3% of the 
time.
It is easy to see why the selective processes of nature help 
cysteine residues remain in a fixed position so well. Cysteine residues 
are usually involved in disulfide bonds or in the active site of a mole­
cule. If a mutation occurred that destroyed a cysteine residue, that 
particular disulfide bond would not be made or the active site would be 
inactivated. The resulting conformational change of a missing disulfide 
bond of the protein would probably make it inactive as an enzyme or un­
suitable as a structural protein. Therefore such mutations would be 
highly selected against.
Why tryptophan mutations are so strongly selected against is not 
so clear. Tryptophan has only one codon, UGG, so one might think that 
this has something to do with its ability to survive. Although methio­
nine has only one codon, it is more often replaced so this explanation 
in itself is not satisfactory. It is probable that the disappearance of 
methionine would be more typical of a single codon, because any mutation 
of that codon would change the amino acid to something else. The reverse 
mutation back would be unlikely since only one codon codes for it. 
Therefore, it is doubtful that the single codon has a great effect on 
tryptophan immutability.
For an answer to this question, consider the nature of trypto­
phan. It is the largest of the amino acids, contains a ring structure 
and is relatively hydrophobic. Dayhoff (l27) has noted that the larger 
amino acids do not mutate very rapidly, so size must have something to 
do with the tendency of tryptophan mutations to be rejected by natural
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selection. The amino acids that replace tryptophan best are tyrosine and 
phenylalanine (l27). Both of these are large, ring-containing amino 
acids, but the side chain of each only contains 1 ring as opposed to the 
2 rings of tryptophan. Since tryptophan is hydrophobic, it would be 
oriented so that the side chain is pointed into the hydrophobic interior 
of a folded protein. If a mutation occurred, the tryptophan would be re­
placed by a smaller residue. This would leave a hole in the interior of 
the molecule. If the residue replacing it were large and hydrophobic, 
it would fill most of the void, and possibly, there would be little re­
arrangement of the tertiary structure of the protein necessary to fill 
the void. If, on the other hand, the residue was small, a larger hole 
is left, and rearrangement of the protein would result with some modifi­
cation of activity. If the residue were hydrophilic, chain rearrange­
ment would almost certainly take place to expose the side chain to the 
external environment causing loss of biological activity. Therefore, the 
changing of a tryptophan residue to almost anything else could easily 
cause loss of biological activity.
If an IgG chain were cleaved by the oxidation of the tryptophan 
residues, we can predict what should happen. In the case of the light 
chain there are 2 constant tryptophan residues (Figure 5). One of these 
is approximately 35 residues from the N-terminal, and the other is ap­
proximately 148 residues from the N-terminal. Complete cleavage at these 
points should give us 3 polypeptides. One of these polypeptides, the 
N-terminal, should be about 35 residues long. Another, the middle, is 
about 113 residues long and the last or C-terminal peptide would be around 
69 residues in length. Since the molecular weight of the 3 expected pep­
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tides is quite different, it should be possible to separate them by mo­
lecular sieving. The variable region and about 40 residues from the con­
stant region will be contained in the N-terminal and middle section pep­
tides, while the remainder of the constant region will be contained in 
the C-terminal peptide.
An analogous situation can be achieved in the heavy chain. Any 
of the cleavages mentioned earlier (papain, pepsin, trypsin, or cyanogen 
bromide) to give an Fab type fragment produce a polypeptide chain of ap­
proximately the same length as the light chain. The extra constant trypt­
ophan in the heavy chain might not complicate the mixture of products and 
prevent their resolution by gel filtration since it is close to the first 
constant tryptophan. The method of cleavage used to obtain the desired 
fragment was cyanogen bromide cleavage. This method yields a polypeptide 
of about 245 residues in length from the N-terminal half of the heavy 
chain.
There are several methods for the oxidization of tryptophan with 
the resultant cleavage of the adjoining peptide bond. They leave the 
oxidized tryptophan as the C-terminal end of a new peptide. Figure 6 
shows a proposed mechanism for this cleavage. Although N-bromosuccinimide 
was used in the illustration, all of the reagents react through about the 
same mechanism. All of the reagents used for this oxidization have some 
drawbacks. They do not achieve 100^ yields of chain cleavage, although 
all tryptophan molecules are oxidized. Other amino acid residues espe­
cially tyrosine and histidine can also be oxidized.
One of the most commonly used reagents for the oxidization of 
tryptophan and the one used for these experiments is N-bromosuccinimide.
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Fig. 6 - The reaction of tryptophan with N-bromosuccinimide to produce chain cleavage.
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Witkop (l28, 129, 130) has studied this reaction and discussed its appli­
cation to protein chemistry. The cleavage takes place through the for­
mation of a lactone structure. The formation of the lactone also causes 
the formation of a Schiff's base involving the nitrogen in the peptide 
chain. Addition of water to this Schiff's base causes the elimination 
of the nitrogen and the resulting cleavages of the peptide bond. The 
method produces a wide range in yield of bond cleavage, generally about 
50^. There are several solvent systems that can be used for this reac­
tion. For our purposes, it was decided to use a solvent of 8 M urea 
titrated to pH 4 with acetic acid. This solvent has two advantages over 
other solvent systems that were proposed. The 8 M urea serves to destroy 
tertiary structure exposing any tryptophan residues in the interior of 
the molecule to the reagent. It also serves to protect the tyrosine from 
oxidization at the concentration of reagent used to oxidize tryptophan, 
since the bromo urea intermediate is much slower at oxidizing tyrosine 
than tryptophan.
Another oxidation procedure for tryptophan has been reported by 
Atassi (l3l). In this method oxidation and cleavage are achieved in dif­
ferent steps, so the conditions are adjusted to achieve maximum yields. 
This procedure may eventually be the best for cleavage of immunoglobulin 
chains. It has the advantage of being able to achieve almost 100% cleav­
age of some particular peptide bonds, but on the other hand, some oxi­
dized tryptophan bonds are not hydrolitically cleaved to any appreciable 
extent. Modification of tyrosine and methionine residues was reported 
as a side reaction of this procedure, but no chain cleavage occurred at 
these residues.
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A third method for the oxidization of tryptophan has recently 
been published by Omenn et al. (l32). 2-(2-nitrophenylsulfenyl)-3-meth- 
ylindole was treated with N-bromosuccinimide. The product was then used 
to treat tryptophan containing peptides and proteins. The cleavage 
yields of this reaction were on the same order as those for N-bromosuc­
cinimide. The great advantage of this reagent over N-bromosuccinimide 
is that it is specific for tryptophan and causes no side reactions with 
other amino acid residues.
The purpose of this work was to first prepare the light chains 
and N-terminal half of the heavy chains. Secondly, these fractions were 
to be oxidized by N-bromosuccinimide to produce cleavage at tryptophan 
residues. Thirdly, the products of this cleavage were to be isolated 
and characterized by N-terminal analysis, amino acid composition and 
peptides produced from them by proteolytic enzymes of known specificity. 
The products of the oxidation of light chains and the N-terminal half of 
the heavy chain can then be compared to previously published sequences 
and structure.
CHAPTER II 
METHODS AND MATERIALS 
Materials
The chemicals used were reagent grade or where necessary, ana­
lytical grade, and were purchased from various suppliers and used without 
further purification with one exception. Pyridine was redistilled after 
refluxing with ninhydrin to free it from reactive amines. The rabbit 
serum was purchased from Pel-Freez Bio-Animals, Inc., Rogers, Arkansas.
Methods
Operations, reactions and centrifugation were conducted at room 
temperature unless otherwise stated. Dialyses and vacuum dialysis were 
carried out in the cold room at 4°C.
Isolation of IgG
Two methods were used for the isolation of the IgG from the rab­
bit serum. The first method involved the use of sodium sulfate precipi­
tation (133) followed by DEAE cellulose chromatography (l34). The sec­
ond method utilizes caprylic acid (octanoic acid) to precipitate nearly 
all the protein in serum except IgG (l3b).
A volume of rabbit serum was precipitated with 3 volumes of sat­
urated (24^) sodium sulfate. The solution was centrifuged at 4080 x g
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for 15 minutes and the supernatant was discarded. The precipitate was 
redissolved in its original volume of water. Saturated sodium sulfate 
was added to make the solution 6% with respect to sodium sulfate, and if 
any precipitate was present in the solution, it was centrifuged and the 
precipitate discarded. More saturated sodium sulfate was added to make 
the solution 12% with respect to sodium sulfate and it was centrifuged 
again. The precipitate was saved. The supernatant was made 18% with re­
spect to sodium sulfate with further addition of saturated solution and 
was again centrifuged. The precipitate was saved and the supernatant 
was discarded.
The 6-12% fraction from the sodium sulfate precipitate was re­
dissolved in 0.15 M sodium chloride and dialyzed against several changes 
of 0.0175 M phosphate buffer at pH 6.3. A column of Bio Rad Cellex-D, 
an anion exchange cellulose, was poured and equilibrated with 0.0175 M 
phosphate buffer at pH 6.3. The column bed was 76 x 5 cm. The 6-12% 
fraction was added to the column and the chromatogram was allowed to de­
velop. After the first 2 peaks had been eluted from the column, the buf­
fer was changed to 0.5 N sodium acetate and 0.5 N sodium chloride at pH
5.5. The column was further developed until no more protein was eluted 
from it. The separate peaks were pooled, dialyzed, and lyophilized. 
Polyacrylamide gel electrophoresis, double iramuno-diffusion, and Immuno­
electrophoresis were run on these pools to check for purity.
The 12-18% fraction was dialyzed against water, lyophilized and 
stored in a freezer at -20°C until used. It was redissolved in 0.0175 M 
phosphate buffer at pH 6.3 and placed on a Bio Rad Cellex-D column equi­
librated in the same buffer. The column was developed with that buffer
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until the first peak had been eluted. It was then eluted with 2 M sodium 
chloride. Only the first peak was used. Disc gels were run to check 
the purity of the first peak.
The isolation of IgG from serum does not take quite as long with 
the use of caprylic acid, so this method was adopted after it was pub­
lished (135). Rabbit serum was diluted with 2 volumes of 0.06 M acetate 
buffer at pH 4. The pH of the final solution was 4.8 + 0.05 or it was 
adjusted to this pH. Caprylic acid, 6.8 g per 100 ml serum, was slowly 
added to the solution with vigorous stirring and the mixture was allowed 
to stir for 30 additional minutes at room temperature. The solution was 
centrifuged for 15 minutes at 4080 x g. The supernatant was saved, and 
the precipitate was resuspended in the same volume acetate buffer as ori­
ginally added. This buffer was 0.015 M acetate at pH 4.8. The resus­
pension of the precipitate was aided by the use of a blender. The sus­
pension was recentrifuged. The 2 supernatants were combined and filtered 
with a Buchner funnel and Whatman #1 paper to remove particles, mainly 
lipid, that had floated while centrifuging. The pH of the solution was 
adjusted to 5.7 and the ionic strength lowered by dialysis against 0.015 
M acetate buffer. The salt concentration of the solution inside the di­
alysis bags was checked by freezing point depression. After the solution 
reached the freezing point of -0.09°C, it was batch absorbed with DEAE 
cellulose to remove small amount of impurities. A quantity of 12 grams 
of humid pressed DEAE-cellulose in equilibrium with 0.015 M acetate at 
pH 5.7 was used for every 100 ml of starting serum. The mixture is 
stirred for 15 minutes and a Buchner funnel was used to remove the DEAE 
cellulose from the solution. The solution was concentrated by vacuum
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dialysis, dialyzed against water and lyophilized. The final product was 
tested for purity by disc gel electrophoresis.
Chain Separation
Two methods were also used to separate the light from the heavy 
chains. The first method was used by Fleischman et ai.. (l9), in which 
the chains were partially reduced and blocked and chromatographed in pro­
pionic acid. The second method was complete reduction and blocking in 
8 M urea.
For partial reduction a 2% solution of protein was made in 0.55 
M Tris with 5 x 10”^ M EDTA at pH 8.2. In order to remove oxygen from 
the solution it was placed in a desiccator and stirred with a magnetic 
stirrer. The desiccator was evacuated with a vacuum pump until the solu­
tion started to foam. The pump was turned off and the solution was al­
lowed to stir for a few more minutes under the vacuum. Nitrogen was then 
allowed to fill the desiccator and the solution was allowed to stir for 
another few minutes. The desiccator was reevacuated and refilled with 
nitrogen again. Mercaptoethanol was added dropwise to a concentration 
of 0.75 M. The solution was allowed to stand in the covered desiccator 
for 1 hour. The flask containing the solution was put in a cold water 
bath and a pH electrode was introduced. Ethylenimine was added slowly 
to a concentration of 0.75 M and the pH was kept at 8.2 by the addition 
of 6 N hydrochloric acid. The reaction mixture was allowed to stand in 
the covered desiccator for thirty minutes. It was then transferred to 
dialysis tubing and dialyzed against.0.1 M sodium chloride. After 3-4 
changes of the dialysis medium the solution was dialyzed against 1 M 
propionic acid.
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A column 5 x 150 cm was poured with Sephadex G-lOO in 1 N prop­
ionic acid. The reaction mixture was chromatographed on this column to 
achieve chain separation. The peaks from the column were pooled sepa­
rately. The chains in solution were precipitated with the addition of 
solid ammonium sulfate to 50% saturation for heavy chains and 65% satura­
tion for light chains. The protein subfractions were suspended in a 
smaller volume of 0.1 M sodium chloride solution, dialyzed against water 
and lyophilized.
The chains were next completely reduced and blocked. They were 
dissolved in 8 M urea in 0.55 M Tris with 5 x 10”  ^M EDTA at pH 8.2 
giving a 2% solution of protein. Oxygen was removed from the solution 
as described before. Mercaptoethanol was added to the solution dropwise 
with stirring to a final concentration of 0.1 M. The solution was al­
lowed to stand overnight. Ethylenimine was added to a final concentra­
tion of 0.12 M and the solution was allowed to stand for 15 minutes.
More mercaptoethanol was added to make the total mercaptoethanol in the 
solution 0.13 M. The solution was then dialyzed against water and lyo­
philized.
Additionally, separation of the chains was achieved by complete 
reduction and blocking of the whole IgG molecule according to the pro­
cedure described for individual chains in the previous paragraph, fol­
lowed by chromatography on a 5 x 150 cm column poured with Sephadex G-200 
in 8 M urea at pH 6. After the chromatogram had developed the peaks were 
pooled, dialyzed against water and lyophilized.
Cyanogen Bromide Cleavage of Heavy Chains
Cyanogen bromide cleavage of the heavy chain proceeded according
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to Givol and Porter (73). The amount of 88% formic acid added was cal­
culated to give a 2% solution of the protein in 70% formic acid. The 
protein was dissolved in this amount of formic acid. Cyanogen bromide 
was weighed out in an amount that was twice the weight of the protein.
It was dissolved in the amount of water required to make the 88% formic 
acid a 70% solution. The cyanogen bromide solution was added to the 
formic acid and protein solution and was allowed to stand in a covered 
desiccator for 24 hours. An amount of cold water 10 times the volume of 
the 70% formic acid solution was added and the resulting solution was 
lyophilized. A small portion of the product was hydrolyzed for amino 
acid analysis to determine completeness of the reaction. The protein was 
dissolved in 1 M acetic acid and chromatographed on a Sephadex G-lOO col­
umn, 4 X 100 cm, equilibrated in 1 N acetic acid. After the chromato­
gram had developed the peaks were pooled. The first peak, the Cl frac­
tion, was lyophilized and cleaved further with N-bromosuccinimide.
N-Bromosuccinimide Cleavage 
N-bromosuccinimide cleavage of the heavy chain Cl fraction and 
light chains was done as described by Ramachandran and Witkop (l29). The 
amount of N-bromosuccinimide to be used was first determined for both 
chains by the UV spectrum of the peptides treated with it. A solution 
of approximately 0.5 mg per ml protein in 8 M urea at pH 4 was scanned 
from 320 to 240 m|i. Small amounts of N-bromosuccinimide were added to 
the solution and after each addition of N-bromosuccinimide another scan 
of the solution was made. The 280 m|i peak decreased and then started to 
increase again. The point where the 280 m^ reading started to increase 
was taken as the end point. The amount of N-bromosuccinimide was calcu-
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lated. Both chains used approximately 12 moles of N-bromosuccinimide 
per mole of polypeptide chain.
A 2% solution of the light chains was made in 8 M urea adjusted 
to pH 4 with acetic acid. N-bromosuccinimide in the amount of 12 moles 
per mole of protein was dissolved in a small volume of 8 M urea at pH 4. 
This was added to the protein solution and mixed. After 5 minutes the 
solution was placed on a Sephadex G-15 column, 2 x 100 cm, in 1 N acetic 
acid to desalt the protein. After desalting, the protein solution from 
the column was concentrated by flash evaporation and placed on a Sephadex 
G-lOO column, 195 x 2.5 cm, equilibrated in 1 N acetic acid. After the 
chromatogram had been developed, the peaks were pooled and the amino acid 
analysis of the peaks was done.
The heavy chain Cl fraction was treated much the same way. Oxi­
dation took place in the same manner, but desalting was done in 50^ ace­
tic acid and the G-lOO column was chromatographed in 25% acetic acid.
The peaks from the chromatogram v/ere rechromatographed on the same column 
for further purification. They were flash evaporated to dryness and re­
dissolved in a known volume of acetic acid at a concentration sufficient 
for complete solution. The peaks were analyzed for their amino acid con­
tent and end group.
Trypsin Digests and Peptide Maps 
Trypsin digests were done in a 1 - 2% solution of the protein. 
The polypeptide material was dissolved in water or dilute sodium hydrox­
ide. A few crystals of metacresol purple were added as a pH indicator 
and the pH of the solution was adjusted to the transition point of the 
indicator, pH 8.0. Trypsin was dissolved in 10"^ M hydrochloric acid and
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a ratio of 1 to 50 of trypsin to protein was added to the protein solu­
tion. The pH was adjusted to the transition point of metacresol purple 
with the addition of 10'^ M sodium hydroxide. The solution was incubated 
at 37°C for 2-3 hour and the pH of the solution was kept adjusted to the 
transition point of metacresol purple with the addition of 10”^ M sodium 
hydroxide. The reaction was stopped by the addition of 0.3 volumes of 
acetic acid.
Peptide maps were made by Dowex 50 chromatography with a peptide 
monitoring system developed by Delaney (l25). A gradient was developed 
by two gradient chambers in series. The first chamber contained 500 ml 
of 0.05 N pyridine in 2 N acetic acid and the second contained 500 ml of 
2 N pyridine in 2 N acetic acid. The columns used were 0.9 x 60 cm and 
1.2 X 60 cm containing Dowex 50 x 8. They were developed at a flow rate 
of 60 ml per hour. A portion of the effluent from the column was di­
verted for peptide analysis and the rest was collected in a fraction col­
lector. The column effluent at 6 ml per hour was added to 6 ml per hour 
of 3 N sodium hydroxide by a proportioning pump and the solution was 
pumped for about 1 hour through coils which passed through a 97°C heat­
ing bath. A solution of 0.5 M borate containing 0.05% trinitrobenzene- 
sulfonic acid was added at a rate of 18.4 ml per hour to the solution 
from the heating bath. This solution was pumped through coils at room 
temperature for about 40 minutes to allow the trinitrobenzenesulfonic 
acid to develop color. The solution was passed through a flow cell and 
the optical density at 430 mp was recorded. The contents of the tubes 
from the fraction collector representing each peak were pooled and flash 
evaporated. They were dissolved in a known amount of water or acetic
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acid and stored frozen.
Paper Electrophoresis 
Paper electrophoresis was used for further purification of pep­
tides and for ionic charge determination (l36) of aspartic and glutamic 
acid containing peptides. The peptides were electrophoresed at pH 6.5,
3.5, and 2.1 for purification and at pH 6.5 and 2.1 to determine the 
ionic charge. The electrophoreses were run in an electrophoresis tank 
at 3000 volts for varying periods of time.
N-Terminal Analysis and Sequence Determinations 
The N-terminal amino acid of the larger peptides was determined 
by a dansyl chloride procedure described by Gray (l37). Approximately 
5 nmoles of the peptide were transferred to a small test tube (6 x 50 mm) 
and dried. A solution of 0.2 M sodium bicarbonate in the amount of 10 p.1
and 10 |xl of dansyl chloride in acetone was added (2.5 mg dansyl chlo­
ride per ml acetone). The pH of the solution was checked on pH paper to 
make sure it was approximately pH 9. If the pH was too low, it was ad­
justed by the addition of more sodium bicarbonate. The tubes were cov­
ered with parafilm and the reaction was allowed to proceed at 37” for 1 
hour. The solutions were dried and 50 p,l of constant boiling hydrochloric 
acid were added. The tubes were sealed and incubated overnight at 105°C. 
The hydrochloric acid was removed in a vacuum desiccator and the residue
was dissolved in 10 p.1 of 50^ pyridine and 50% water.
The end groups were identified by 2 dimensional chromatography 
on polyamide layer sheets (l38). The dansyl hydrolysate was spotted on 
polyamide layer sheets. Half was spotted on each side of a sheet and on
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one of these spots was placed a standard mixture of dansyl amino acids. 
The chromatogram was developed in the first direction by a water-88% 
formic acid solvent (200:3, v/v). The second direction was developed in 
benzene-glacial acetic acid (9:1, v/v). Identification of the end groups 
was done by comparison under a UV lamp of the spots on the standard con­
taining side of the sheet with the spots on the other side. If the chro­
matogram contained spots for aspartic and glutamic acid or threonine and 
serine a third solvent, n-heptane-n-butanol-glacial acetic acid (3:3:1 
by volume) was used to separate these pairs of spots.
Sequence determinations were done with 2 methods of Edman de­
gradations described by Gray (l39, 140). In the first method a peptide 
solution was transferred to a small screw cap test tube (3-5 ml). It was 
dried by flash evaporation. To the dried peptide were added 100 pi of 
b% phenylisothiocyanate in pyridine and 100 pi of water. The test tube 
was flushed with nitrogen and incubated at 45“C for 1 hour. The solution 
was dried by flash evaporation and 200 pi trifluoroacetic acid was added 
to the tube. It was incubated for 30 minutes at 45°C and dried by flash 
evaporation. Water, 250 pi, was added and the solution was extracted 3 
times with 250 pi of butyl acetate. An aliquot containing 1-5 nmoles 
was taken for dansylation and the remainder of the solution was dried by 
flash evaporation for another cycle of Edman degradation. As more cycles 
of Edman degradation are run, more of the peptide material is lost by 
side reactions which form products that do not undergo cyclization and 
release of the N-terminal amino acid, by extraction into the butyl ace­
tate layer of the extracting system and by use in the dansyl procedure.
So each step requires a larger aliquot for the dansyl procedure than the
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step before. If a 10 residue peptide were to be sequenced, it would re­
quire 0.1 pmole or more of peptide to sequence the peptide. The first 
aliquot would only require about 1-2^ of the sample and later aliquots 
for dansylation would require high percentages until, in the final step, 
100% of the sample is taken. It is also clear that a short degradation 
by this method requires little material, but longer ones call for much 
higher amounts.
The aliquot taken for dansylation was placed in a 6 x 50 mm test 
tube and dried under a vacuum in a desiccator. After 20 p.1 of 0.05 M 
sodium bicarbonate was added to the tube, it was dried again to remove 
ammonia from the sample. Deionized water, 10 |il, was added to the dried 
residue in the tube and the pH of the resulting solution was checked by 
spotting a little on pH paper. The pH should be approximately 9. Next,
10 |il of 2.5 mg dansyl chloride per ml acetone were added and the solu­
tion was incubated for 1 hour at 37°C. The contents were then dried in 
the desiccator and 25 pi of constant boiling hydrochloric acid were added 
to the tube. After it was sealed, the tube was heated at 105’C overnight. 
The hydrochloric acid was dried and the dansyl amino acid was identified 
by polyamide layer sheet chromatography as described above.
The second method used for sequencing peptides was a later de­
velopment by Gray (l40) for use on short (5-6 residues or shorter) pep­
tides. A peptide, 5-10 nmoles, was placed in several appropriately la­
beled 6 X 50 mm test tubes. One test tube was used for each amino acid 
residue in the peptide to be sequenced. The contents of the tubes were 
dried in a vacuum desiccator that was heated to 70°C. The tube contain­
ing the sample to be analyzed for the N-terminal residue was set aside.
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To the other test tubes were added 50 |il of freshly made coupling mix­
ture (600 jj.1 of a 5% solution of phenylisothiocyanate in pyridine and 
400 |il of water). The test tubes were covered with parafilm and incu­
bated at 50'C for 45 minutes. The samples were then dried in the desic­
cator and 50 p.1 of trifluoroacetic acid was added to them. They were al­
lowed to stand in the heated desiccator for 10 minutes after which they 
were dried. The tube containing the sample to be analyzed for the sec­
ond residue was set aside and another Edman cycle was performed on the 
contents of other tubes. After each cycle, the tube representing the 
newly exposed residue was set aside. After about 5 cycles, the residue 
in the test tubes became difficult to dry and this placed a practical 
limit on the number of residues that could be sequenced by this method.
It was possible to obtain a few more cycles by extracting this residue 
with the water/ethyl acetate extracting system as explained below.
After the Edman degradation cycles were completed, 40 pi of the 
aqueous phase of a water/ethyl acetate system was added to all the test 
tubes on which Edman cycles had been performed. These samples were ex­
tracted 3 times with 200 pi of the ethyl acetate phase to remove excess 
reagent and by-products. The contents remaining in the tubes were dried 
in the heated desiccator.
All samples were then dansylated. After 10 pi of 0.2 M sodium 
bicarbonate was added to the test tubes, the contents were dried to re­
move ammonia. Deionized water, 15 pi, was added to the samples and the 
pH of the solution was checked to be sure it was approximately pH 9. If 
the pH was correct, 15 pi of a solution of 3 mg dansyl chloride per ml 
of acetone was added to the sample tubes and they were covered with para-
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film. The tubes were incubated at 50'C for 15 minutes. The samples were 
dried and 100 p,l of constant boiling hydrochloric acid was added. The 
tubes were sealed and incubated at 105°C overnight. The tubes were then 
dried and extracted twice with 100 pi of the ethyl acetate phase of the 
water/ethyl acetate system described above. The ethyl acetate was trans­
ferred to another properly labeled test tube and dried. The residue was 
dissolved in 50^ water-50% pyridine and run on the polyamide layer sheets 
as described before.
Protein Hydrolysis 
Hydrolysis of proteins and peptides for amino acid analysis was 
done with constant boiling hydrochloric acid. After the sample to be 
hydrolyzed was placed in a test tube, it was dried and 1 ml of constant 
boiling hydrochloric acid was added. The tube was stretched, evacuated, 
and sealed with an oxygen torch flame. The hydrolysis tubes were placed 
in a heating block maintained at 110°C for 24 hours. The hydrochloric 
acid was removed by flash evaporation and the residue was dissolved in 
2.5 ml of pH 2.2, 0.2 N citrate buffer. The amino acid analysis was done 
on a BioCal BioChrom Amino Acid Analyzer with a sample injector using a 
2 column system.
Polyacrylamide Gel Electrophoresis 
Polyacrylamide gel electrophoresis was run on a Canalco Model 6 
apparatus. Standard gels in 4 x 66 mm tubes were used. They were 1% 
acylamide with a pH of 9.5. The stacking gel has a pH of 8.9 and an 
acrylamide concentration of 1.25%. A Tris-glycine buffer at pH 8.2 was 
used in the upper and lower baths. A tracking dye, bromphenol blue, was
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placed in the upper bath. After sample application the gels were elec- 
trophoresed at 5 ma per tube until the tracking dye nearly reached the 
bottom of the gel. The gels were stained with aniline black in 1% acetic 
acid and destaining was done by electrophoresis using 1% acetic acid in 
both the top and bottom bath of the apparatus.
Immunoelectrophoresis 
Immunoelectrophoresis was done using a Gelman apparatus. The 
electrophoresis was run in a 1% agar gel containing Gelman High Resolu­
tion Buffer on 1" x 3" microscope slides. After sample application to 
the agar, the electrophoresis was run at 360 volts for 45 minutes. After 
electrophoresis, the center strip was removed from the agar and goat-anti 
rabbit serum was placed in the center trough. After the precipitate 
lines had formed in the agar, the gels were rinsed in 0.9% sodium chlo­
ride overnight to elute any protein not precipitated. They were rinsed 
with distilled water and stained with aniline black. The slides were 
then rinsed with 1% acetic acid to remove excess stain and dried.
Double Immunodiffusion 
Double immunodiffusion was done on a 3" x 5" glass slide. A 1% 
agar solution was poured on the glass about l/32" thick and allowed to 
harden. Wells were cut in the agar, and the outside wells were filled 
with fractions from the DEAE cellulose column. The center well was 
filled with goat anti-rabbit serum. After bands developed (approximately 
2 days) the agar was washed, stained and dried as described above.
CHAPTER III
RESULTS
A total of 25 gm of nonspecific rabbit IgG was isolated from 
pooled rabbit serum by 2 methods. The first method involved sodium sul­
fate precipitation followed by DEAE cellulose chromatography. The pro­
file of the DEAE cellulose chromatography is shown in Figure 7. The 
peaks were pooled and the purity of each peak was checked by polyacryl­
amide gel electrophoresis shown in Figure 8, double diffusion in Figure 
9, and by immunoelectrophoresis in Figure 10.
All of the checks for purity show that peaks A and B are quite 
clean preparations of IgG. The double diffusion plate and disc gel show 
only one band for these two peaks and the immunoelectrophoresis also 
shows them to be a fairly homogeneous preparation of IgG. The immuno­
electrophoresis for peak B seems to have a flaw in the agar gel causing 
the IgG band to be unsymmetrical but the preparation has only 1 band. 
Peak I is nearly all IgG as shown by the purity checks. The disc gel 
shows only 1 faint band in addition to the IgG and the double diffusion 
plate shows 2 faint bands; one in the first half of the peak and a dif­
ferent one in the second half. The immunoelectrophoresis for peak I 
shows no band in addition to the IgG.
The other peaks were not as pure. Peak II shows 2 extra bands
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Fig. 7 - DEAE cellulose chromatography of rabbit IgG.
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Fig. 8 - Polyacrylamide gel electrophoresis of IgG fractions.
Fractions 1, 2, 3, 4 and 5 are fractions A, B, I, II and III 
from the DEAE cellulose fractionation of rabbit IgG. Fractions 6 and 7 
are the 12-18^ sodium sulfate fraction before and after DEAE cellulose 
chromatography. Fraction 8 is the IgG isolated with caprylic acid.
peaks.
Fig. 9 - Double immunodiffusion of DEAE cellulose fractionation
The center well contains goat anti-rabbit serum. Wells 1 and 2 
contain the center and tail from peak A. Wells 3, 4 and 5 contain the 
front, center and back of peak I. Well 6 contains peak II.
A48
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Fig. 10 - The immunoelectrophoresis of IgG fractions from DEAE 
cellulose chromatography.
The fractions are numbered as they eluted from the column, ex­
cept fraction IV. Fraction IV is the 12-18% sodium sulfate fraction.
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on disc gel and at least 2 faint bands by double diffusion. Immunoelec­
trophoresis also shows at least 2 extra bands. Peak III shows several 
bands by both immunoelectrophoresis and disc gel. Peak III is too con­
taminated to use for further experiments with the IgG but Peak II seems 
to have very little contamination in relation to the total amount of IgG, 
so it was used.
The 12-18% sodium sulfate fraction was contaminated with several 
other proteins as shown by both disc gel and immunoelectrophoresis. 
Chromatography of this fraction on DEAE ce.lulose yielded 2 fractions.
The first, corresponding in elution to peak A and B, was about as clean 
as peak I as shown by disc gel electrophoresis and was also used.
The second method for isolation of the rabbit IgG used a caprylic 
acid precipitation of serum proteins which leaves IgG in solution. This 
fractionation produced a nearly pure IgG contaminated with small amounts 
of IgA and ceruloplasmin (l27). These contaminants were removed by batch 
absorption with DEAE cellulose. The purity of these preparations was 
checked by polyacrylamide gel electrophoresis which is shown in gel 8, 
Figure 8. This preparation shows at least 4 faint bands in addition to 
the IgG band, but they are all very faint in comparison to the IgG band. 
These bands, therefore, constitute only a small portion of the total pro­
tein in the preparation. This fraction was also used.
Two methods for the isolation of light and heavy chains from the 
purified IgG were tried. Whereas the products obtained are of comparable 
purity, the shorter method of preparation (complete reduction in 8 M 
urea) has a serious drawback that makes the other method more preferable. 
The long exposure of protein to urea leads to some reaction of lysine
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residues with a breakdown product of urea, cyanate. After 3-4 days in 
8 M urea at room temperature, 20-30% of the lysine has carbamylated.
The chain separation by the two methods is shown in Figures 11 
and 12. Each chromatogram on Sephadex G-200 and G-lOO contains 3 peaks.
In each chromatogram, the first peak contains heavy chain dimers and/or 
aggregates, the second peak contains heavy chain monomers and the third 
peak contains only light chains. In most reports in the literature (l9) 
this separation is done on Sephadex G-75 which chromatographs all of the 
heavy chains in the first peak. The weight of heavy chain (peak I and 
II) to light chain (peak III) in these preparations was always in the 
range of 2 to 1 which indicates a good yield of chain cleavage. The 
amino acid composition of the light and heavy chains is given in Table 2.
The light chains were used first for tryptophan oxidation be­
cause of several factors. They were pure by-products of our fractiona­
tion. The light chain has only 2 constant tryptophan residues and would 
present a simpler pattern than the Cl fraction which has 3. Finally, the 
light chain is about 20 residues shorter than the heavy chain, so we would 
expect a better separation from the C-terminal and middle sections of the 
molecule.
The UV spectrum of the unoxidized light chains was recorded. 
N-bromosuccinimide was added until the absorbance at 280 mp, went through 
a minimum. This occurred at 12 moles N-bromosuccinimide per mole of 
light chain. The spectra of the unoxidized and oxidized light chains 
are shown in Figure 13.
After treatment with N-bromosuccinimide, the desalted light 
chains were then chromatographed on G-100. The results are shown in
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Fig. 11 - Chain separation in propionic acid.
Rabbit IgG was partially reduced and blocked and chromatographed 
on Sephadex G-100. The column was 5 x 150 cm, and was equilibrated and 
run in 1 N propionic acid.
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Fig. 12 - Chain separation in 8 M urea.
Rabbit IgG was completely reduced and blocked and chromatographed 
on Sephadex G-200 in 8 M urea. The column was 5 x 150 cm.
TABLE 2
AMINO ACID COMPOSITION OF LIGHT CHAINS, HEAVY CHAINS AND Cl FRACTION
Amino
Acid
Heavy
Chain
Residues
Heavy
Chain®
Light
Chain
Residues
Light
Chain®
Cl
Fraction
Residues
Cl ,
Fraction®
Aspartic Acid 32.3 7.6 18.3 8.8 13.7 5.9
Threonine 46.2 10.8 22.9 11.0 32.8 14.0
Serine 47.1 11.0 23.9 11.5 30.9 13.2
Glutamic Acid 39.1 9.2 22.4 10.7 16.4 7.0
Proline 41.2 9.7 14.6 7.0 20.3 8.7
Glycine 30.9 7.2 19.6 9.4 22.4 9.6
Alanine 22.1 5.2 13.4 6.4 15.7 6.7
Valine 43.9 10.3 19.6 9.4 24.1 10.3
Cystine 12 - 5 - 8 -
Methionine 6.7 1.6 1.0 0.5 - -
Isoleucine 15.8 7.3 7.4 3.5 5.8 2.5
Leucine 29.0 6.8 11.3 5.4 17.9 7.6
Tyrosine 16.6 3.9 10.5 5.0 10.4 4.5
Phenylalanine 14.7 3.5 6.7 3.2 8.2 3.5
Lysine 18.3 4.3 11.4 5.5 7.9 3.4
Histidine 6.1 1.4 1.5 0.7 0.9 0.4
Arginine 16.2 3.8 4.6 2.2 6.5 2.8
Tryptophan^ 8 - 3 - 4 -
Total 446 100 217 100 246 100
^Calculated without including tryptophan and cystine. Expressed as residues per 100 residues. 
^Estimated amounts from literature.
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Fig. 13 - The spectra of unreacted and oxidized light chains.
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Figure 14. The amino acid composition of the peaks is shown in Table 3. 
There was very little amino acid material in peak F. It consisted mainly 
of bromourea which absorbes at 280 mp.
The N-terminal amino acid for each of the peaks was determined. 
All of the peaks showed multiple end groups. Peak B had an end group of 
tyrosine, threonine and serine. Peak C contained tyrosine, aspartic 
acid, glutamic acid, alanine and serine. Peak D contained lysine, tyro­
sine and aspartic acid, and peak E contained threonine, serine, glycine, 
alanine and lysine. These peaks were not rechromatographed.
The heavy chains (500 mg) were treated with cyanogen bromide 
and the resultant polypeptides were chromatographed on G-100. This chro­
matogram is shown in Figure 15. The first peak off the column contained 
the N-terminal half of the heavy chain. The amino acid composition of 
this peak is given in Table 2.
Work on the Cl fraction from the heavy chain was then started.
A flow chart showing the reactions of the heavy chain is shown in Figure 
16. The UV spectrum was used as above to determine the correct amount of 
N-bromosuccinimide to use. As in the light chain, 12 moles of N-bromo­
succinimide per mole of Cl were required. The UV spectra are shown in 
Figure 17.
The Cl chains (250 mg) were treated with 12 moles of N-bromosuc­
cinimide per mole of chain in a final volume of 12.5 ml and were desalt­
ed. The resulting peptides proved to be too hydrophobic to remain in so­
lution in 1 N acetic acid. It was finally determined that 25%' acetic 
acid would keep them in solution, so after desalting, they were chromat­
ographed on Sephadex G-100 in that solution. The chromatogram that de-
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Fig. 14 - Chromatography of N-bromosuccinimide treated light chains.
The column was Sephadex G-100, 2.5 x 195 cm, and it was equilibrated with 1 N acetic acid.
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TABLE 3
RELATIVE COMPOSITION OF FRAGMENTS OBTAINED 
FROM NBS OXIDIZED LIGHT CHAIN
Amino
Acid A B C
Peaks®
D E F
Aspartic Acid 8.2 9.0 8.8 10.1 8.8 9.6
Threonine 12.2 11.8 8.7 16.2 14.4 5.7
Serine 11.7 11.2 7.9 13.9 15.6 6.1
Glutamic Acid 8.3 10.4 9.2 10.8 10.3 8.8
Proline 5.2 6.5 7.3 4.6 3.2 4.1
Glycine 10.9 9.0 9.2 8.8 9.7 9.4
Alanine 8.7 6.9 8.3 4.4 10.0 12.4
Valine 8.7 8.0 9.5 7.3 8.6 6.0
Methionine 0.4 tr 0.7 0.1 0.9 0.8
Isoleucine 3.5 3.0 4.1 2.3 3.6 3.6
Leucine 5.0 5.0 6.5 5.9 4.8 7.5
Tyrosine 4.8 4.2 2.9 3.6 2.1 1.9
Phenylalanine 3.9 3.3 3.5 2.6 1.3 3.2
Lysine 5.9 7.1 8.2 5.3 4.1 5.7
Histidine 0.3 1.8 1.5 1.2 0.8 2.3
Arginine 2.4 2.9 3.8 2.8 1.6 12.7
^Residues per 100 residues.
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Fig. 15 - Chromatography of CNBr treated heavy chains. 
The column was 4 x 100 cm and was run in 1 N acetic acid.
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Fig. 16 - Flow chart of reactions of the heavy chains and the 
resulting fractions.
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Fig. 17 - The spectra of unreacted and oxidized Cl.
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veloped (Figure 18) looked somewhat like the chromatogram from the light 
chain, but on closer examination, it was quite obvious that it was much 
different. Peaks B, C, D and E were rechromatographed on the same column 
for further purification. Peak D, on rechromatography (Figure 19), 
yielded 2 fractions (DI and DIl), The amino acid composition of the 
peaks (B, C, DI, DII and E after rechromatography) were determined and 
are given in Table 4. Like the last peak from the light chains, there 
was very little peptide material in peak G.
Amino-terminal analysis of the peaks was carried out. Peak B 
after rechromatography had end groups of tyrosine, glycine and alanine. 
Peak C after rechromatography gave a predominant glycine end group with 
a trace of threonine and serine. Peak E, before rechromatography, gave 
end groups of glycine, alanine, valine, isoleucine, leucine and tyrosine.
The peaks B, C, DI, DII and E were lyophilized and weighed.
From a 300 mg preparation of Cl the approximate yield of the various 
fractions were 36 mg for B, 30 mg for C, 60 mg for DI, 20 mg for DII 
and 35 mg for peak E. This corresponds to 12%, 10%, 20%, 7% and 12% of 
the total starting material for each peak respectively.
Peak 0 was digested with trypsin and the peptide map was de­
veloped from a Dowex 50 column (Figure 20). Pools were made represent­
ing each peak. Amino acid analysis of the pools was done. Peptides 
from peaks ClCb and ClCc were judged homogeneous on the basis of their 
compositions and were not purified further. Peptide ClCd was further 
purified by paper electrophoresis at pH 6.5. This peptide gave a yellow 
cadmium-ninhydrin spot which indicates a glycine end group. ClCe and 
ClCf were obtained by paper electrophoresis at pH 3.5 of the first 3
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Fig. 18 - Chromatography of N-bromosuccinimide treated Cl fraction on G-100.
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Fig. 19 - The rechromatography of peak D.
TABLE 4
RELATIVE COMPOSITION OF FRAGMENTS OBTAINED 
FROM NBS OXIDIZED Cl FRACTIONS
Amino
Acid A B C
Peaks^
DI DII E F G
Aspartic Acid 8.3 7.0 7.7 8.0 7.2 7.3 6.1 11.0
Threonine 11.8 13.6 12.8 13.2 12.9 13.7 13.6 6.8
Serine 12.4 12.1 14.7 13.2 14.0 11.8 14.5 13.9
Glutamic Acid 7.2 6.1 5.4 7.3 5.9 8.2 8.7 8.3
Proline 5.7 10.9 11.7 9.9 12.6 6.7 5.4 5.4
Glycine 9.7 8.1 7.1 10.6 7.5 9.6 11.2 11.6
Alanine 7.9 5.5 5.5 5.5 5.2 5.7 7.0 8.8
Valine 9.8 10.7 10.0 7.7 10.6 7.7 8.4 10.4
Isoleucine 4.9 2.5 2.0 3.6 2.1 3.6 3.6 5.1
Leucine 7.2 8.2 7.2 6.9 7.4 7.6 8.1 5.0
Tyrosine 4.0 2.8 2.3 3.4 2.0 3.8 3.7 3.6
Phenylalanine 3.5 3.5 3.4 3.1 3.7 3.2 2.9 3.0
Lysine 4.2 5.3 5.4 4.8 5.1 6.3 3.1 2.9
Histidine 0.7 0.8 1.6 0.7 1.3 1.5 0.8 1.1
Arginine 2.7 3.0 3.2 2.0 2.6 3.4 2.9 2.9
O'
^Residues per 100 residues.
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Fig. 20 - The peptide map of peak C.
Peaks b, c and d are listed in Table 5 as ClCb, ClCc and CiCd.
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peaks from the Dowex 50 column. ClCa was purified by Sephadex G-25 chro­
matography of the section of the chromatogram between ClCd and the next 
peak. The amino acid composition of these peptides is shown in Table 5.
Another preparation of peak C was made and digested by trypsin. 
These peptides were separated on Sephadex G-25 (Figure 21) and were fur­
ther purified by paper electrophoresis. In addition to the peptides iso­
lated from the Dowex 50 peptide map, 2 other peptides that were the re­
sult of tryptic hydrolysis at aminoethylcysteine were also isolated. The 
composition of the peptides ClCg and ClCh are also listed in Table 5.
Peptides ClCe and ClCf gave at least 2 ninhydrin spots each.
The amino acid compositions of these peptides are given in Table 5. The 
amino acid compositions of the 2 ClCe peptides are quite similar, and the 
compositions of the ClCf peptides are also similar. Further digestion of 
the 2 ClCe peptides was attempted with chymotrypsin and thermolysin, but 
no meaningful data was obtained from these experiments. Because Cebra 
(78) had published the sequence of a peptide from the same position as 
ClCf, no further work was undertaken at that time on these 2 peptides to 
find the differences between them. Further work on these peptides is 
hampered by the difficulty of obtaining enough of a homogeneous peptide 
to recover further digestion products in good yield.
Peptides ClCb, ClCc, ClCd, ClCg and ClCh were sequentially de­
graded by the Edman method. The results are shown in Figure 22. Elec­
trophoretic mobilities of ClCd and ClCg indicated that the acidic resi­
dues in these 2 peptides were all in the amide form. The sequence of 
ClCd is tentative because the position of the glutamine residue has not 
been established.
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TABLE 5
COMPOSITION OF TRYPTIC PEPTIDES OBTAINED FROM Cl FRACTIONS
Amino
Acid ClCa ClCb ClCc ClCdb ClCel
Residues
ClCe2
Aspartic Acid 0.9 0.9 0.2 1.8 2.2
Threonine 0.8 1.1 1.0 4.0 4.2
Serine 1.1 1.0 6.2 5.2
Glutamic Acid 0.8 2.2 2.6
Proline 1.0 0.9 3.4 2.8
Glycine 1.8 2.4 2.5
Alanine 0.2 1.8 1.8
Valine 0.6 0.9 1.3 4.1 4.5
Aminoethylcysteine® 1 1
Isoleucine 0.4 0.7
Leucine 1.0 0.8 2.6 2.2
Tyrosine 0.6 0.8
Phenylalanine 1.0 0.9 0.8
Lysine 1.0 1.1 0.7 0.6
Histidine tr tr
Arginine 1.0
Homoserine® 1
^Estimated values. 
^72-hour hydrolysis.
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TABLE 5— Continued
ClCfl ClCf2 ClCg ClCh ClDIIa ClDIIb ClDIIc ClBa ClBb
1.2 0.4 2.0 1.6 0.8 0.9
3.0 1.9 1.7 1.6 2.0 1.1 1.2
3.7 3.2 1.0 1.2 1.1 1.1
1.2 0.5
8.1 9.0 1.1 1.0 1.0 1.0
2.7 3.2 1.7
1.6 0.5 2.1 1.2 0.4
2.1 1.6 1.0 1.2 1.0 0.9 1.0 0.9 0.9
2 2 1
0.6 1.2
2.6 3.1
0.2
1.4 2.3 1.0 0.9
2.7 4.2 1.1
1.0
0.3
0.8
1.0
0.8
1.0
0.9
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Fig. 21 - The chromatography of a trypsin digest of peak C.
The chromatography was done on a Sephadex G-25 column, 1.5 x 100 
cm in 1 N acetic acid.
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ClCb
Va^-^-Lys
ClCc
Thi^ -Ph^-Pro^ -Se:^ -Va]^ -Arg 
ClCd
Gly-Se^-Gl^-Thr-Leu-Va]^-Pro-Val(Gln )Lys 
ClCg
Asn-Val-Al^(His)Pr( -^Al^-Thr-Asi^ -Thr-Lys
ClCh
Thr-Va^-Al^-Pro(Ser,Thr)AECys
Fig. 22 - The amino acid sequence of peptides isolated from 
trypsin digests of peak C.
Residues that have not been established are in brackets. No
residue could be identified from the 3rd Edman cycle on peptide ClCg.
Histidine is placed in this position by homology.
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Peak E was digested with trypsin and the peptide map of this 
peak was developed (Figure 23). Pools were made representing each of the 
peaks. The pools were analyzed for amino acid content and further puri­
fied by paper electrophoresis at various pH's. No homogeneous peptides 
could be purified from these pools as determined by amino acid ratios.
Peptide maps were also obtained for peaks B and DII (Figures 24 
and 25). A few peaks from these chromatograms were subjected to amino 
acid analysis. The results are given in Table 5.
The peaks from oxidation of light chains and Cl fraction were 
assigned to particular positions in these polypeptide chains for reasons 
discussed in the next Chapter. With this knowledge, the molecular weight 
of each peak can be estimated, and the compositions of these peaks can 
be expressed as residues/mole. This is done in Table 6. In addition, 
the yield of each of the Cl fractions can also be calculated, and these 
are also shown in Table 6. The effective molecular weight of each of 
the fractions is also given in Table 6. The effective molecular weight 
on the G-lOO column of each fraction is higher than the actual molecular 
weight because they were chromatographed in high ionic strength solvents.
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Fig. 24 - The peptide map of peak B.
Peaks a and b are listed in Table 5 as ClBa and ClBb.
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Fig. 25 - The peptide map of peak DII.
Peaks a, b and c are listed in Table 5 as ClDIIa, ClDIIb and ClDIIc.
TABLE 6
FRACTIONS FROM LIGHT CHAINS AND Cl EXPRESSED AS RESIDUES/MOLE
Amino Light Chains Cl Fraction
Acid B C D E B C D1 Dill E F
Aspartic Acid 15.7 9.5 6.8 3.0 14.1 6.5 12.3 6.0 8.6 2.1
Threonine 20.5 9.5 10.9 4.9 27.4 10.8 20.2 10.9 16.0 4.6
Serine 19.6 8.6 9.3 5.3 24.2 12.4 20.2 11.7 13.8 4.9
Glutamic Acid 18.2 10.0 7.2 3.5 12.2 4.5 11.2 4.9 9.6 3.0
Proline 11.4 7.9 3.1 1.1 21.9 9.9 15.1 10.6 7.8 1.8
Glycine 15.8 10.0 5.9 3.3 16.2 5.9 16.2 6.3 11.2 3.8
Alanine 12.0 9.0 3.0 3.4 11.1 4.6 8.5 4.3 6.7 2.4
Valine 13.9 10.3 4.9 2.9 21.6 8.4 11.7 8.9 9.0 2.9
Cysteine^ 4 2 2 1 7 3 5 3 4 1
Methionine tr 0.8 tr 0.3 - - - - - -
Isoleucine 5.2 4.5 1.6 1.2 5.0 1.7 5.6 1.8 4.2 1.2
Leucine 9.4 7.1 4.0 1.6 16.4 6.1 10.5 6.2 8.8 2.8
Tyrosine 7.8 3.1 2.4 0.7 5.6 1.9 5.2 1.7 4.5 1.3
Phenylalanine 5.8 3.8 1.7 0.4 7.1 2.9 4.7 3.1 3.8 1.0
Lysine 12.4 8.9 3.5 1.4 10.6 4.5 7.4 4.3 7.3 1.0
Histidine 3.1 1.6 0.8 0.3 1.5 1.3 1.1 1.1 1.8 0.3
Arginine 5.0 4.1 1.9 0.5 6.0 2.7 3.1 2.2 3.9 1.0
Tryptophan® 1 1 0 1 1 0 1 0 1 1
Total
Effective Molec­
181 112 69 36 210 88 158 88 122 36
ular Weight 
% Yield
34,000 20,000 10,200 6,300 52,000
14
42,000
28
27,000
20 31
14,000
19
10,200
CJÏ
^Estimated value
CHAPTER IV
DISCUSSION
One thought that should be kept in mind is that pooled IgG is a 
heterogeneous protein. Any isolation or chemical reaction of such a pro­
tein runs the risk of selecting from the various proteins only a portion 
of the many types from the whole. A good example of this is the DEAE 
cellulose chromatography after sodium sulfate precipitation. Although 
there was much IgG in the peak III and the second peak from the 12-18% 
fraction, these fractions could not be used because of the impurity. 
Therefore, any IgG molecule that tended to adsorb to the DEAE cellulose 
was selected against. The consequence of this is that the complete spec­
trum of IgG molecules was not achieved. The caprylic acid precipitation 
method yields nearly 100% IgG in the first step, but the batch absorption 
on DEAE cellulose removes a small portion of the IgG. This selection is 
small in comparison to DEAE cellulose chromatography but still exists.
The selectivity can appear in nearly every operation carried out on the 
IgG and can lead to some misinterpretation of the experimental data.
The N-bromosuccinimide cleavage of the light chain yielded the 
expected results. The first peak, peak A, probably contained uncleaved 
material and aggregates of light chains and peptides. Its amino acid 
composition was not identical with that of whole light chains, but it
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was not greatly different. Peak B was assigned to the overlap peptide 
containing the C-terminal and middle sections of the light chain. The 
amino acid composition is fairly close to that of the light chain, which 
would be expected, but even more important its composition is close to 
the average composition between peaks C and D. Peaks C and D are as­
signed to the middle and C-terminal polypeptides respectively. Peak E 
is principally the N-terminal peptide. The effective molecular weight 
data agrees with this assignment. The weight of C plus D (30,000) is 
near that of B (34,000).
Since very little work has been done on the sequence of pooled 
rabbit light chains it is difficult to predict with an accuracy the com­
position of any of the fragments from rabbit light chains. Therefore, 
the amino acid composition of a peak is, by itself, not strong enough 
proof to be able to say for certain that a given peak represents a cer­
tain fraction. On the other hand indications may be drawn from these 
compositions. The constant portion of several human kappa chains pre­
viously sequenced (l27) could give an indication of the possible compo­
sition of the C-terminal fragment of the rabbit chain. In some of the 
amino acid compositions of the various peaks from the oxidized light 
chains there are large differences in the values of individual amino 
acids. For instance, in peak D the total threonine + serine content is 
30.1% and in peak C it is only 16.6%. Other comparisons of these 2 peaks 
show proline to be 4.6% for peak D and 7.3% for peak C and alanine to be 
4.4% and 8.3%, respectively. Human kappa chains show approximately 27% 
threonine + serine, 4.5% alanine and 1.5% proline for the C-terminal pep­
tide. Each of these values is much closer to the peak D value than to
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the peak C value. The only big exception to these indications is lysine. 
Peak D has 5.3% lysine and peak C has 8.2% lysine. Human kappa chains 
have 9% lysine. Some doubt about the correct lysine values exists be­
cause of the side reaction of the lysine with cyanate produced by urea. 
Even with the one exception noted the amino acid composition seems to 
indicate that peak D is the C-terminal peptide.
There is an even more compelling reason to assign peak D to the 
C-terminal position. It elutes from the Sephadex column later than peak 
C, and therefore has a lower effective molecular weight. This is what 
our model predicted would be the order of elution from the column.
The reasons for assigning peak C to the middle section of the 
molecule have already been given. It has a higher effective molecular 
weight than D and its amino acid composition and the composition of peak 
D average to the composition of peak B. There are 3 exceptions to this 
average composition. There is more histidine and tyrosine and less leu­
cine in peak B than in either C or D. It is possible that the tyrosine 
and histidine in the shorter chains were oxidized by the N-bromosuccin­
imide to a small extent. Also, the small amount of histidine was diffi­
cult to calculate on the amino acid analysis because it is incompletely 
resolved from aminoethylcysteine appearing before it and the ammonia 
peak appearing after it. This makes it difficult to draw an accurate 
base line for the calculation. There is no obvious explanation why the 
leucine value is outside the average.
Peak E was assigned to the N-terminal peptide mainly because of 
the effective molecular weight of its peak. Since this peptide comes 
from the variable region of the light chain, the amino acid composition
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of other kappa chain peptides can only show tendencies in composition.
In human and mouse light chains (l27), methionine shows up in this pep­
tide relatively frequently and peak E has the highest methionine content 
of any of the peptides. Threonine and serine also occur quite often in 
sequenced kappa chains while proline appears only about once or twice per 
peptide. Basic amino acids represent only about 2 residues for each N- 
terminal peptide. All of these tendencies are present in peak E. Amino 
acid composition supports the assignment of E to the N-terminal peptide.
Although the N-terminal amino acid analysis showed several 
dansyl amino acids for each of the peaks, the residues that are expected 
are among these spots. Human and mouse myeloma kappa chains are followed 
by tyrosine, leucine, or phenylalanine in position 36 and lysine in po­
sition 148 (127). Rabbit light chains have aspartic acid and alanine at 
their N-terminal (23). Peak D contains lysine as an end group and peak 
B and peak C contain tyrosine. Peak E contains alanine. Unpublished 
data of Mameesh and Delaney indicate that if peak C is extensively re­
purified, a homogeneous end group of tyrosine can be obtained. All of 
the evidence obtained from the chromatography of N-bromosuccinimide 
treated light chain is consistent with predictions from the model. This 
information is consistent with the existence of the predicted 2 constant 
tryptophanes in all rabbit light chains, and probably all immunoglobulin 
light chains.
In contrast to the light chains, the heavy chain Cl fraction 
did not yield the expected chromatographic pattern. At first glance, 
the pattern of this chromatogram appears to be similar to that of the 
light chain, but there are several important differences.
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Unlike the light chain, it was possible to estimate the compo­
sition of the N-bromosuccinimide fractions with some degree of accuracy. 
Cebra (77) has published the composition of the C-terminal 70 residues.
By using the sequence of Eu or some other sequenced heavy chain, it was 
possible to predict the next 15 residues or so up to the tryptophan num­
ber 158. Using Wilkinson's data as reported by Porter (l4l), the compo­
sition of the N-terminal 34 residues was given, so it was not hard to 
estimate the composition for the N-terminal section. The N-terminal and 
C-terminal composition was subtracted from the complete Cl fraction com­
position to obtain the expected composition of the middle section. The 
resultant compositions were converted to mole per cent. These expected 
compositions and the compositions of the peptides that are assigned to 
the N-terminal, C-terminal and middle sections are presented for compari­
son in Table 7.
Since the C-terminal polypeptide chain contains the hinge sec­
tion of the heavy chain, it should have a high percentage of proline.
This one amino acid is probably the best marker in the entire molecule. 
Peak C contains a high amount of proline. The other amino acid percent­
ages of peak C are fairly close to the predicted values for the C-termin­
al fraction. By amino acid composition data, peak C is assigned to the 
C-terminal peptide. This assignment immediately raises the question of 
why peak C elutes from the column so early? Its predicted molecular 
weight would indicate that it should elute after peak E. The hinge re­
gion, which contains the high proline content, may prevent the polypep­
tide chain from assuming a globular shape. This would cause the effec­
tive molecular weight to be much higher due to a larger Stake's axis of
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TABLE 7
COMPARISON OF PREDICTED AND DETERMINED COMPOSITIONS 
OF Cl FRACTIONSa
Amino
Acid
Predicted
N-Terminal
Peak
F
Predicted
C-Terminal
Peak
C
Predicted
Middle
Peak
E
Aspartic Acid 2.9 6.1 6.0 7.7 6.8 7.3
Threonine 14.7 13.6 11.9 12.8 15.4 13.7
Serine 17.6 14.5 14.3 14.7 11.1 11.8
Glutamic Acid 8.8 8.7 3.6 5.4 8.5 8.2
Proline 5.9 5.4 15.5 11.7 4.3 6.7
Glycine 11.8 11.2 7.1 7.1 10.3 9.6
Alanine 2.9 7.0 6.0 5.5 8.5 5.7
Valine 11.8 8.4 11.9 10.0 8.5 7.7
Isoleucine 0.0 3.6 1.2 2.0 4.3 3.6
Leucine 11.8 8.1 8.3 7.2 6.0 7.6
Tyrosine 2.9 3.7 1.2 2.3 6.8 3.8
Phenylalanine 2.9 2.9 3.6 3.4 3.4 3.2
Lysine 2.9 3.1 6.0 5.4 1.7 6.3
Histidine 0.0 0.8 2.4 1.6 0.0 1.5
Arginine 2.9 2.9 1.2 3.2 4.3 3.4
Expressed as residues per 100 residues.
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symmetry.
Peak F is assigned to the N-terminal polypeptide of the molecule 
for several reasons. The amino acid composition is consistent with the 
predicted value in most cases. Alanine and aspartic acid are the most 
notable exceptions to this, but even these seemingly large differences 
are only on the order of one residue from the predicted values. This 
peak is approximately in the same position on the chromatogram as the 
N-terminal peak from the light chain and it shows the same amino acid 
characteristics pointed out for the light chain. It has about 28?^  thre­
onine plus serine, 2 prolines and 2 basic residues.
Peak E is assigned to the middle section of the Cl fraction.
The amino acid composition is about as predicted. One notable exception 
to this is lysine. The way the predicted value for lysine was reached 
led to a large error in the value. About l/3 of the lysine was lost by 
chemical modification during chain separation. Peaks C and F contained 
little of these modified residues. Therefore the predicted value for the 
middle section appears too low. Published values (77) for the composi­
tion of the Cl fraction show it to contain about 12 lysine residues or 
4 more than shown in this Cl fraction. If these 4 residues are added to 
the predicted composition of peak E, the actual results are in closer 
agreement to the predicted result.
The average of peaks C and E seems to approximate the composi­
tion of B and the effective molecular weight of C plus E (56,000) is 
close to that of B (52,000). There are several amino acid mole per cents 
in B that fall outside the range formed by E and C but all are very close 
to either E or C. In all but one of these cases, valine, the difference
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between E and C is quite small.
The identity of peak DI has not been firmly established. A pos­
sibility for the identification of this peak is the overlap of the middle 
section and the N-terminal section. The predicted molecular weight of 
this peptide would place it in the chromatogram somewhere between peak B 
and E, and that is where peak DI is located. Also, the effective molec­
ular weight of E plus F (24,000) is close to that of DI (27,000). Since 
the middle section would make up about 3/4 of the amino acid residues in 
this proposed overlap peptide, the amino acid composition would be ex­
pected to show a similarity between peak DI and E. DI and E have similar 
compositions except for proline. Since the peptides on either side of 
DI, DII and C, both have high proline compositions, a little contamina­
tion of DI with either or both of these peaks would raise the proline 
content markedly. A peptide map of DI could establish whether this poly­
peptide is the overlap between the N-terminal and middle section of Cl.
Peak DII appears to be a C-terminal polypeptide much like peak 
C. Their amino acid compositions are quite similar, but some differences 
between the 2 peptides must exist since they do not chromatograph in the 
same position. Peak DII also seems to average with peak E to obtain the 
composition of peak B even better than peak C. Peak A appears to be un­
cleaved material and/or aggregates of polypeptides. Its amino acid com­
position is not greatly unlike that of Cl.
N-terminal analysis of the peaks gave a variety of amino acids 
in each case, but the expected end group was usually among them. Peak B 
has an expected tryosine or isoleucine end group, and tyrosine was pres­
ent. The expected end group for peak C was aspartic acid but no aspartic
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acid was found. Instead, peak C gave a very predominant glycine end 
group. Peak E would be expected to contain tyrosine or isoleucine and 
contained both.
All of the peptides that Cebra's (78) C-terminal polypeptide,
T2, contained were isolated from the fractions obtained from the column. 
They were peptides ClCa, ClCb, ClCe and ClCf. This was conclusive proof 
that peak C was the C-terminal peptide. In addition to the T2 peptides, 
two more peptides were obtained, ClCc and ClCd. The peptides ClCb and 
ClCc chromatographed late in the development of the column and therefore 
make good markers for the C-terminal polypeptide.
The peptide map of peak E showed neither of the two marker peaks 
from the C-terminal. This peptide map consisted mainly of two large 
peaks near the start of the run. The peptide map adds more confidence 
to the assignment of E as the middle section of the Cl fraction.
The peptide map of peak B showed both the characteristic marker 
peaks from the C-terminal section and the large peptide peaks early in 
the run characteristic of the middle section, peak E. Amino acid anal­
yses of the suspected C-terminal marker peaks showed compositions identi­
cal to ClCb and ClCc. This added confirmation to the fact that peak B 
contains both the C-terminal and middle sections of Cl.
Peak DII showed the 2 characteristic peaks from the C-terminal 
section, and amino acid analysis confirmed that the composition of these 
peaks is identical to the corresponding peaks from peak C. Total peptide 
material in the peptide map in comparison to the size of the ClCb and 
ClCc peaks makes it unlikely that large amounts of anything but the C- 
terminal polypeptide are present. Although this peptide map is somewhat
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different from the map of peak C, peak DII is a C-terminal peptide.
The sequences of some of the peptides from peak C were compared 
to the sequences of the same sections reported by Porter's group (79) and 
the myeloma protein Eu (86) (Figure 26) and the alignment of peptides is 
shown in Figure 27. The amino acid sequence of ClCb and ClCc and the 
composition of ClCa agree with those reported by Hill et _al. (75) and 
Porter's group (79). Peptides ClCe and ClCf were not sequenced here, 
but 2 smaller peptides, ClCg and ClCh, which arose from tryptic hydroly­
sis at aminoethylcysteine, were partially sequenced. ClCh has the same 
amino acid composition as reported by Cebra (77) and the first 4 residues 
are in the order reported. There are probably no differences between 
ClCh and the remaining sequence of Cebra's. Peptide ClCg shows a proline 
residue that Fruchter (79) did not include in this peptide. A proline 
appears in the corresponding peptide from Eu, but it is one residue re­
moved from being in the same position. Electrophoretic mobility of ClCg 
shows both of the aspartic acid residues are amides.
Peptide ClCd (Figure 26) contains some of the differences be­
tween fraction ClC and Fruchter's (79) sequence. The amino acid compo­
sitions of ClCd and the corresponding peptide from Fruchter are different, 
but there is little doubt that the two peptides come from the same loca­
tion. They both contain the tetrapeptide Ser-Gly-Thr-Leu. The trypsin 
digest of peak DII yields the peptide, ClDIIa, which has a composition 
identical to that of Fruchter's sequence. This peptide is one of the ob­
vious differences between peaks C and DII and adds further confirmation 
to the identity of peak DII. The difference between peaks C and DII is 
probably greater than allotypic differences and is more likely a subtype
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ClCb Val-Asp-Lys 
RaIgG Val-Asp-Lys 
Eu Val-Asp-Lys
ClCc Thr-Phe-Pro-Ser-Val-Arg 
RaIgG Thr-Phe-Pro-Ser-Val-Arg 
Eu Thr-Phe-Pro-Ala-Val-Leu
ClCd Gly-Ser-Gly-Thr-Leu-Val-Pro-Val(Gln)Lys
RaIgG Asn-Ser-Gly-Thr-Leu-Thr-Asp-Gly-Val-Arg 
Eu Asn-Ser-Gly-Ala-Leu-Thr-Ser-Gly-Val-His
ClCg Asn-Val-Ala(His)Pro-Ala-Thr-Asn-Thr-Lys
RaIgG Asx-Val-Ala-His-Ala - Thr-Asx-Thr-Lys 
Eu Asn-Val-Asn-His-Lys-Pro-Ser-Asn-Thr-Lys
ClCh Thr-Val-Ala-Pro(Ser,Thr)Cys 
RaIgG Thr-Val-Ala-Pro-Ser-Thr-Cys 
Eu Lys-Val-Gln-Pro-Lys-Ser-Cys
Fig. 26 - Comparison of the amino acid sequences from peak C 
peptides with the sequences for rabbit IgG reported by Fruchter (79) and 
with the myeloma protein Eu (86).
87
110
Asx-Leu(Gly,Gly,Leu,Val,Thr)Val-Ser-Glx“Pro-Ser-Gly-Thr-Lys-
125
Ala-Pro-Ser-Val-Phe-Pro-Leu-Ala-Pro-Cys-Cys-Gly-Asp-Thr-Pro-
140
Ser-Ser-Thr-Val-Thr-Leu-Gly-Cys-Leu-Val-Lys-Gly-Tyr-Leu-Pro-
155 Peak DI and E / Peak C and DII -» 
Glu-Pro-Val-Thr-Val-Thr-TRP-Asn-Ser-Gly-Thr-Leu-Thr-Asp-Gly-
---ClCd and ClDIIa—————————
170
Val-Arg-Thr-Phe-Pro-Ser-Val-Arg-Gln-Ser-Ser-Gly-Leu-Tyr-Ser- 
ClCc and ClDIIc————/ ---------------------------
185
Val-Pro-Ser-Thr-Val-Ser-Val-Ser-Glx-Pro(Pro,Ser)Thr-Cys-Asx-
---------------------- ClCel and ClCe2 --------------------
/--
200
Val-Ala-His-Ala-Thr-Asx-Thr-Lys-Val-Asp-Lys-Thr-Val-Ala-Pro- 
———————————————————————————————yClCb and———/ ———————————————
---------- ClCg------- -----— / ClDIIb / ------ ClCh---
215
Ser-Thr-Cys-Ser-Lys-Pro-Thr-Cys-Pro-Pro-Pro-Glu-Leu-Leu-Gly-
.......   ClCfl and ClCf2..............
  /
230
Gly-Pro-Ser-Val-Phe-Ile-Phe-Lys-Pro-Pro-Pro-Lys-Asp-Thr-Leu- 
------------------------------— -------— -----/ --ClCa-----
Met 
— /
Fig. 27 - The sequence of rabbit Cl fractions from residue 109 
to the C-terminal (79) and the location of isolated peptides.
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difference as in the human subtypes.
The composition of peak DII is closer to the composition of the 
polypeptide sequenced by Porter's group than is the composition of peak 
C. If the IgG sequenced by Porter's group also had sequences like that 
of my peak C, the method of isolation selectively isolated the peptides 
that were like peak DII.
If oxidation and cleavage occurred at any residue besides trypt­
ophan, the most likely amino acid to be affected would be tyrosine. Cl 
chains had 10.4 tyrosines per chain as shown in Table 2. If the tyrosine 
compositions of the peptides from Table 6 are added together in accord­
ance with the position assignments of the peptides, the totals range from 
6.9 (B + F or DI + DII) to a maximum of 7.7 (C + E + F) residues of ty­
rosine per Cl chain. This represents a loss of about l/3 of the total 
tyrosine. An examination of the loss is therefore necessary.
Although peak A (Table 4) has a lower tyrosine percentage than 
Cl, it is richer in tyrosine than the other fractions. The apparently 
low recovery of tyrosine could be partially explained by the appearance 
in peak A of peptides with high tyrosine content. It can not be stated 
at this time why this happens, but at least three possibilities exist; 
high tyrosine peptides do not cleave by oxidation, high tyrosine peptides 
tend to aggregate or peptides that are cleaved tend to lose their ty­
rosine by some mechanism.
The first question to be considered is, did an actual loss of 
tyrosine take place or is 10.4 residues of tyrosine an artifically high 
number for some reason? Fruchter's (79) sequence of rabbit heavy chains 
shows 2 tyrosine residues from residue 110 to the end of the Cl fraction.
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Fleischman's (80) sequence of the first 65 residues shows 4 tyrosines.
The myeloma protein Eu shows 5 tyrosines for the intervening 45 residues 
in the Cl fraction. The loss of tyrosine is most likely an actual loss. 
On the other hand, Fleischman's Cl fraction contained only 7.4 residues, 
so individual Cl chains do not all contain the higher number of residues.
There are 3 possible explanations for the loss of the tyrosine; 
oxidation of specific residues, random oxidation, and/or loss through 
some other mechanism not involving oxidation, such as destruction during 
acid hydrolysis.
Fruchter's and Fleischman's sequences indicate that the C-ter­
minal and N-terminal peaks each have 1 residue of tyrosine. Peaks C,
DII and E have 1.9, 1.7 and 1.3 residues of tyrosine respectively, there­
fore any specific oxidation and cleavage at tyrosine residues would most 
likely be confined to the center section of the Cl chain. This is where 
all of the tyrosine shortages in Table 6 appear. These facts are incon­
sistent with random oxidation and cleavage at tyrosine residues, but are, 
in themselves, not strong enough to rule out the possibility.
If specific oxidation and cleavage at some of the tyrosine resi­
dues took place, the peptides that would result would be smaller in mo­
lecular weight than E peak peptides and would probably elute from the 
column in the neighborhood of peaks F and G. G contains little peptide 
material, so peak F would be expected to contain most of any specific 
tyrosine cleavage products. Peak F is not big enough to contain a great 
quantity of these products, and it would also be expected to contain 
products from cleavages at variable tryptophans. Therefore, cleavage at 
specific tyrosine residues can not be excluded, but it is unlikely that
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it occurs to any great extent.
An argument has already been advanced against random cleavage at 
tyrosine residues, but further consideration is warranted. If l/3 of the 
tyrosine residues were randomly oxidized and 100^ cleavage occurred, only 
a 30% yield would result. Complete cleavage is unlikely, so a much lower 
yield would probably result. As mentioned in the previous paragraph, 
these peptides that were released would tend to fall into the chromato­
gram in the region of peak F. Therefore, random cleavage, if it occurs, 
does not likely proceed to a very large extent.
If oxidation is the cause of the loss of tyrosine, some predic­
tions can be made concerning it. It is most likely an oxidation of spec­
ific tyrosine residues in the middle section of the Cl chain, and the 
oxidation does not lead to cleavage of the polypeptide chain in the maj­
ority of cases.
A third possibility exists that the tyrosine residues were lost 
by some other mechanism not involving oxidation. One argument for his 
possibility is that Cebra (77) recovered about 6 of his 9.4 tyrosine 
residues from his fractionation which did not involve any oxidation.
This loss is about the same ratio of loss that tryptophan oxidation 
shows, so the loss may not be due to oxidation. Cebra's procedures in­
cluded a fractionation on Sephadex as did these experiments. A very 
hydrophobic peptide containing most of the tyrosine residues (the middle 
section peptide is both hydrophobic and high in tyrosine) may have been 
lost in both fractionations.
Another possibility for loss of tyrosine is during acid hydroly­
sis. No extra precautions were taken to prevent this, but normal pre-
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cautions were taken. Constant boiling hydrochloric acid was used for
hydrolysis in an evacuated, Pyrex test tube.
To sum up these arguments, a loss of tyrosine occurred that is 
confined to the middle section of the Cl chains. Some of this loss can 
be explained by selective appearance of peptides that contain high amounts 
of tyrosine in peak A. Other losses of tyrosine besides oxidation have 
been discussed. It is also possible that oxidation and cleavage of ty­
rosine residues has occurred, but it is unlikely that this reaction oc­
curred to a large extent.
On the other hand, it is possible to show most of the cleavage 
occurred at tryptophan residues. The oxidation spectra from the chains 
indicated tryptophan oxidation (loss of OD at 280 mp). Unfortunately, 
calculation of the amount of tryptophan oxidized was not possible because 
of the 280 mp. absorption of the bromourea complex.
From previously sequenced rabbit chains, a predicted composition
of the products was made. The isolated products were compared to these 
predicted compositions and found to be close except where earlier noted. 
Among these peptides were found 2 peptides that could only have come from 
the C-terminal portion of the Cl fragment. This was proved by showing 
that they contained peptides (ClCb, ClCc, ClDIIb and ClDIIc) which had 
been previously shown by Cebra (77) to come from this section of the mol­
ecule. In addition, other peptides were found (ClCd and ClDIIa) that 
could have only arisen by chain cleavage of the tryptophan at residue 
160 (Fruchter's numbering. Figure 27). Fruchter's sequence from residue 
160 to 165 is -Trp-Asn-Ser-Gly-Thr-Leu-. Peak C had a glycine end group 
and peptide ClCd had a sequence of Gly-Ser-Gly-Thr-Leu-. So, the homol­
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ogy between these 2 sequences is very strong. Peptide CiDIIa had a com­
position that is identical to that of the corresponding peptide from 
Fruchter's sequence. Peak C and peak DII account for 48% of the total 
C-terminal sections in the original Cl fraction. From previously as­
signed positions we saw that peaks DI and E were the peptides split from 
the C-terminal section, or to put it another way, they also arose from 
the split at residue 158. Peaks DI and E represent 50% of the total mid­
dle section. Therefore, for each C-terminal fraction produced, an intact 
middle section peptide was also produced. If any appreciable amount of 
cleavage at tyrosine residues had occurred within either of these sec­
tions, these ratios would have varied more widely.
The N-bromosuccinimide oxidation of tryptophan has allowed the 
isolation of 2 different peptides that come from the same section of the 
molecule, C and DII. This has shown that in the rabbit, at least, the 
constant portion of the Fd chain is not as constant as had been thought 
and may indicate subtype differences. Little work has been done on the 
DII peptides, but the peak C peptides have been studied enough tc show 
some tendencies. There is an obvious difference between the N-terminal 
peptides from fractions C and DII, but differences also show up between 
some peak C peptides studied. Peptides ClCel and ClCe2 have different 
amino acid compositions and electrophoretic mobilities as do peptides 
ClCfl and CiCf2. Therefore, differences exist even between peak C pep­
tides which come from the same position. This indicates the nature of 
the problem that Porter's group overcame in isolating peptides homogene­
ous enough to sequence from this section of the molecule.
The oxidation of tryptophan by N-bromosuccinimide to produce
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chain cleavage has been known for several years, but the method has never 
been widely used because of the low yields of peptide bond hydrolysis 
that it produces. Because of this low yield, nearly any other chain 
cleavage method has been used in preference to it. In this paper, an ap­
plication has been shown that may be preferable to the method used by 
Porter's group (77) to obtain the sequence. They obtained their peptides 
by blocking lysine and digesting with trypsin. Yield data for their 
method was missing, but visual examination of the chromatograms in their 
publications indicates that their yields were not any higher than the 
per cent yields for oxidation with N-bromosuccinimide. Since tryptophan 
is more constant in a sequence than arginine, its invariability, in this 
case, makes it as useful as trypsin digestion. In addition, N-bromosuc­
cinimide cleavage is easier to perform.
The Cl chain is a good example of the type of polypeptide chain 
that can be most effectively cleaved by oxidation. There are no meth­
ionine residues in constant locations, so cyanogen bromide cleavage can 
not be used to cleave the large polypeptide chain into shorter chains. 
N-bromosuccinimide cleavage is an easy and quick method for achieving 
the cleavage of a large polypeptide chain into 2 or 3 smaller polypep­
tide chains. It works best if only 1 or 2 tryptophan residues are pres­
ent in the polypeptide chain. With more tryptophan residues than this, 
the peptide patterns can quickly become complicated by all of the differ­
ent overlapping peptides. In the case of the Cl chain there were 3 con­
stant tryptophan residues, but 2 of them were close enough together that 
the resulting peptides did not differ greatly in size.
This dissertation has demonstrated that the cleavage of light
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chains and heavy chain Cl fractions by tryptophan oxidation is a good 
approach to the structure of these polypeptides. This method also is an 
approach to the separation of the constant and variable regions of IgG. 
N-bromosuccinimide oxidation may not be the most effective method, so 
work should now be done to examine other methods of oxidation to see if 
they are more effective. Atassi's method (l3l) utilizing periodate may 
prove to be more valuable in this application, and Omenn's method (l32) 
using an oxidizing intermediate between N-bromosuccinimide and the 
tryptophan, may also have value. In addition chromatography on Sephadex 
G-lOO superfine might improve separations between the various fractions 
obtained.
CHAPTER V
SUMMARY
Tryptophan appears to be located in relatively constant posi­
tions in IgG chains. These positions are so situated that cleavage of 
these tryptophan residues by oxidation would produce fractions that en­
able the variable and constant region to be separated. Only about 40 
residues of the constant region would be found in the variable fractions.
The constant tryptophan residues are at residue 36 and 148 in 
the light chain. Cleavage at these positions would result in 3 peptides; 
an N-terminal peptide of about 36 residues, a C-terminal peptide of about 
69 residues and a middle section of about 118 residues. Since oxidation 
of tryptophan does not produce 100^ cleavage, overlap peptides would also 
result. These peptides are different sizes and Sephadex chromatography 
should separate them. An analogous situation can be set up in the heavy 
chain by cyanogen bromide cleavage to produce the N-terminal half of the 
heavy chain. The constant tryptophan residues in this fraction are at 
the same approximate locations as those of the light chain.
Rabbit IgG light chains were oxidized by N-bromosuccinimide.
The Sephadex chromatography of the resulting polypeptides yielded 6 peaks. 
The peaks were identified by order of elution and by amino acid analysis. 
The results were as predicted from position of the tryptophan residues.
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The N-bromosuccinimide cleavage of the heavy chain N-terminal 
fraction produced a chromatography that was different than expected. By 
amino acid analysis and peptide mapping the identity of the peaks was 
established. There were 2 different peaks found that each represent the 
C-terminal polypeptide. Although the order of elution of the peptides 
from the Sephadex was not as expected, all the peptides that were ex­
pected were found.
The usefulness of the oxidation of constant tryptophan residues 
in structural work on IgG has been demonstrated. Further work will be 
needed to determine the best method for this oxidation.
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